

Organized by



EUROPEAN SOCIETY FOR  
**CLINICAL VIROLOGY**

[www.escv2018.com](http://www.escv2018.com)



# Final Programme

Under the Auspices



HELLENIC REPUBLIC  
MINISTRY OF TOURISM

23-26 SEPTEMBER - ZAPPEION MEGARON

ATHENS  2018



CITY OF ATHENS

Secretarial Support



Financial Management





# Table of Contents



Committees	04
Welcome Message	05
Programme at a glance	06
Scientific programme	08-15
Sunday 23 September 2018	08
Monday 24 September 2018	10
Tuesday 25 September 2018	12
Wednesday 26 September 2018	14
Posters' index / Poster sessions	16
Faculty index	34

Industry Symposia	38
The 2018 ESCV Awardees	42
General Meeting Information	44-47
Registrations	44
Name badges	45
Certificate of Attendance	47
Accreditation	47
Certificate of Accreditation	47
Presentation Guidelines	49-50
General	49
Oral presentations	49
Supported presentation formats	49
Presentation preview desk	49
In the Auditorium	49
Poster presentations	50

General Information	52
Social Programme	55
Floorplan & exhibitors' list	58
Sponsors' acknowledgement	60





# Committees

## Local Organizing Committee

### Conference Chair

**George Sourvinos** (*Crete, Greece*)

**Emilia Hadziyannis** (*Athens, Greece*)

**Ioannis Karakassiliotis** (*Alexandroupolis, Greece*)

**Panagiotis Markoulatos** (*Thessaly, Greece*)

**Penelope Mavromara** (*Alexandroupolis, Greece*)

**Andreas Mentis** (*Athens, Greece*)

**Anna Papa** (*Thessaloniki, Greece*)

**Nikos Spanakis** (*Athens, Greece*)

**Alexandros Zafiropoulos** (*Crete, Greece*)

## Scientific Programme Committee

**Fausto Baldanti** (*Italy*)

**Javier Buesa** (*Spain*)

**Peter Coyle** (*Qatar*)

**Mariet Feltkamp** (*The Netherlands*)

**Heli Harvala** (*United Kingdom*)

**Paul Klapper** (*United Kingdom*)

**Andreas Mentis** (*Greece*)

**Hubert Niesters** (*The Netherlands*)

**Svein Arne Nordbø** (*Norway*)

**Elizabeth Puchhammer-Stöckl** (*Austria*)

**Elizaveta Padalko** (*Belgium*)

**Paulo Paixão** (*Portugal*)

**Marcus Panning** (*Germany*)

**Anna Papa** (*Greece*)

**George Sourvinos** (*Greece*)

**Nikos Spanakis** (*Greece*)

**Kate Templeton** (*United Kingdom*)

**Pamela Vallely** (*United Kingdom*)

## Abstract Reviewers

**Fausto Baldanti** (*Italy*)

**Peter Coyle** (*Qatar*)

**Susanne Gjeruldsen Dudman** (*Norway*)

**Mariet Feltkamp** (*The Netherlands*)

**Giorgio Gallinella** (*Italy*)

**Heli Harvala** (*United Kingdom*)

**Randall Hayden** (*USA*)

**Paul Klapper** (*United Kingdom*)

**Louis Kroes** (*The Netherlands*)

**Andreas Mentis** (*Greece*)

**Hubert Niesters** (*The Netherlands*)

**Svein Arne Nordbø** (*Norway*)

**Elizaveta Padalko** (*Belgium*)

**Paulo Paixão** (*Portugal*)

**Marcus Panning** (*Germany*)

**Mario Poljak** (*Slovenia*)

**Elisabeth Puchhammer-Stöckl** (*Austria*)

**Anne-Marie Roque-Afonso** (*France*)

**Maria São José Alexandre** (*Portugal*)

**George Sourvinos** (*Greece*)

**Athanasios Tsakris** (*Greece*)

**Pamela Vallely** (*United Kingdom*)

**Alexandra Valsamakis** (*USA*)

**Annemiek van der Eijk** (*The Netherlands*)



## Welcome Message



Dear Colleagues and friends,

It is our great pleasure to invite you to the **21<sup>st</sup> ESCV Annual Meeting** which will be held in Athens, 23-26 September, 2018.

The ESCV Annual Meeting has been a major event for the Clinical Virology scientific community and it is becoming more popular, comprehensive, innovative and influential, while maintaining high standards of scientific quality and a family atmosphere. The 21<sup>st</sup> ESCV Annual Meeting is promising to be an exciting event, covering all timely topics of Clinical Virology, enabling delegates to exchange knowledge with world's leading experts, network with colleagues and discuss the latest advances on "traditional" and emerging viruses.

The ESCV 2018 Scientific Committee is preparing a new inspiring Programme for this event. The Conference will include all of its "classical" features, such as keynote lectures, oral presentations, poster sessions and awards to outstanding clinical virologists. Furthermore, state-of-the-art diagnostic applications on Clinical Virology from leading companies are expected to be presented in industry-sponsored symposia.

Athens, as the host city for the 21<sup>st</sup> ESCV Annual Meeting is an excellent choice since it combines natural beauty, cultural wealth and an array of up-to-date infrastructures that not only guarantee organizational efficiency, but also promise a highly refreshing and pleasurable experience for all participants. Furthermore, Athens is a symbolic city with fundamental contribution in science, philosophy and arts, recognized as the birthplace of the Western civilization and Democracy. Situated in the very heart of Athens, the Congress venue itself, the Zappeion Megaron, is a "living" testament of Greece's long and diverse modern history.

The Local Organizing Committee is fully motivated and will make every possible effort to offer an unforgettable experience for all ESCV 2018 participants, this time with a specific Greek flavour.

We look forward to welcoming you in Athens in September 2018, eager to exchange views on our field and ready to enjoy the marvelous late summer overlooking the Aegean coastline.



**George Sourvinos**  
*Conference Chair*



**Javier Buesa**  
*ESCV President*



# Programme at a Glance

Sunday 23 <sup>rd</sup> September 2018	12.00 - 13.00	<b>Pre-Conference Industry-Sponsored Symposium (in Greek language)</b>
	13.55 - 14.00	<b>Welcome Notes, Chair of 21<sup>st</sup> ESCV AM</b>
	14.00 - 15.30	<b>Session 1: Respiratory Viruses</b> Keynote Lecture Oral presentations (O01-O06) <b>Heine - Medin Award</b>
	15.30 - 16.00	<b>Coffee Break</b>
	16.00 - 17.30	<b>Session 2: Viruses in the immunosuppressed host</b> Keynote Lecture Oral presentations (O07-O12)
	17.30 - 18.45	<b>Session 3: Prevention / Vaccines</b> Keynote Lecture Oral presentations (O13-O15)
	18.45 - 19.45	<b>Industry-Sponsored Symposium</b>
	19.45 - 20.45	<b>Opening Ceremony - Welcome Addresses</b> Opening Lecture: Prof. Harald zur Hausen (Nobel Laureate)
	20.45	<b>Welcome reception</b>

Monday 24 <sup>th</sup> September 2018	08.30 - 09.30	<b>Industry-Sponsored Symposium</b>
	09.30 - 10.30	<b>Session 4: Viral Pathogenesis and Immune Responses</b> Keynote Lecture Oral Presentations (O16-O18)
	10.30 - 11.00	<b>Coffee Break</b>
	11.00 - 12.30	<b>Session 5: Emerging Viruses</b> Gardner Lectureship Oral Presentations (O19-O22)
	12.30 - 14.00	<b>Lunch</b> ESCV Council Meeting (including lunch)
	14.00 - 15.00	<b>Industry-Sponsored Symposium</b>
	15.00 - 16.00	<b>Industry-Sponsored Symposium</b>
	16.00 - 17.30	<b>Session 6: Hepatitis Viruses</b> Keynote Lecture Oral Presentations (O23-O26)
	17.30 - 18.00	<b>Coffee Break</b>
	18.00 - 19.30	<b>Session 7: Congenital &amp; Neonatal Viral Infections</b> Keynote Lecture Oral Presentations (O27-O30)
	19.30 - 21.00	<b>Poster Session (P001-P158)</b>

# Programme at a Glance



Tuesday 25 <sup>th</sup> September 2018	08.30 - 09.30	Industry-Sponsored Symposium
	09.30 - 10.30	Session 8: Diagnostic Advances in Clinical Virology I / Point-of-Care Diagnostics Industry Lecture Award Oral Presentations (O31-O33)
	10.30 - 11.00	Coffee Break
	11.00 - 12.30	Session 9: Viral Gastroenteritis / CNS infections Keynote Lecture Oral Presentations (O34-O37)
	12.30 - 13.30	Lunch - Poster Session (P159-P318) ENPEN Meeting
	13.30 - 14.30	Industry-Sponsored Symposium
	14.30 - 15.30	Industry-Sponsored Symposium
	15.30 - 16.40	Session 10: HIV / Sexually transmitted viral infections Keynote Lecture Oral Presentations (O38-O40)
	16.40 - 17.05	Coffee Break
	17.05 - 18.15	Session 11: Diagnostic Advances in Clinical Virology II / Clinical Metagenomics Keynote Lecture Oral Presentations (O41-O43)
	18.15 - 18.35	ESCV General Assembly
	18.40	Departure for the Greek Night Dinner

Wednesday 26 <sup>th</sup> September 2018	08.30 - 09.30	Industry-Sponsored Symposium
	09.30 - 11.00	Session 12: Viral Oncogenesis Keynote Lecture Oral Presentations (O44-O47)
	11.00 - 11.30	Coffee Break
	11.30 - 12.00	Industry Lecture Award
	12.00 - 13.30	Session 13: Clinical Syndromes Keynote Lecture Oral Presentations (O48-O51)
	13.30 - 14.00	Closing Remarks - Hand over (Presentation of 22 <sup>nd</sup> ESCV meeting)





# Scientific Programme

12.00 - 13.00 **Pre-Conference Industry-Sponsored Symposium (in Greek language)**

13.55 - 14.00 **Welcome Address**  
Chair of the 21<sup>st</sup> ESCV Annual Meeting

14.00 - 15.30 **Session 1  
Respiratory Viruses**  
Chair: Maria So Jos Nascimento, Ron Fouchier

14.00 - 14.30 **Keynote Lecture**  
**Respiratory viruses: progress and gaps**  
Laurent Kaiser (Switzerland)

14.30 - 15.30 **Oral Presentations**

**O01** Influenza B virus of the Yamagata-lineage was the cause of an epidemic 2017/18 influenza season in Denmark  
R. Trebbien  
Statens Serum Institut, Denmark

**O02** Spanish enteroviruses surveillance in respiratory infections and molecular epidemiology of EV-D68, 2014-2018  
R. Gonzlez  
Instituto de Salud Carlos III, Spain

**O03** Molecular characterization of Influenza strains circulated in patients admitted to ICU during the 2017-18 season in Italy  
A. Piralla  
Fondazione IRCCS Policlinico San Matteo, Italy

**O04** Dual-RNAseq enables full genome assembly of measles virus, minority-variant detection and host-pathogen interactions delineation  
T. Karamitros  
Hellenic Pasteur Institute, Greece

**O05** Detailed analysis of influenza B virus infections diagnosed at the Leipzig University Hospital during three consecutive years  
M. Hnemann  
Leipzig University and University Hospital, Germany

**Heine-Medin Award** **O06** Optimization and collection efficiency of different air-samplers to collect infectious aerosolized respiratory viruses from the air  
S. Herfst  
Erasmus MC, The Netherlands

15.30 - 16.00 **Coffee Break**

16.00 - 17.30 **Session 2  
Viruses in the immunosuppressed host**  
Chair: Elisabeth Puchhammer-Stckl, Fausto Baldanti

16.00 - 16.30 **Keynote Lecture**  
**New vaccines and antiviral drugs for CMV**  
Paul Griffiths (UK)

16.30 - 17.30 **Oral Presentations**

**O07** Plasma levels of Torque Teno Virus in HIV-1 infected patients at diagnosis of infection and after one year under treatment  
C. Pronier  
CHU Pontchaillou & IRSET - INSERM UMR 1085 - University of Rennes 1, France

**O08** Metagenomic virus sequencing of living donor-recipient kidney transplant pairs reveals JC Polyomavirus transmission  
V. Kufner  
University of Zurich, Switzerland

# Scientific Programme



Sunday 23<sup>rd</sup> September 2018

- O09** NKG2C Deletion is a Risk Factor for Human Cytomegalovirus-Viremia and Disease after Lung Transplantation  
H. Vietzen  
Medical University of Vienna, Austria
- O10** Pretransplantation BK polyomavirus genotyping by a Luminex immunoassay in donor-recipient pairs shows that infection after kidney transplantation is of donor origin  
M.C.W. Feltkamp  
Leiden University Medical Center, The Netherlands
- O11** Single measurements of TTV as a marker of long-term immunosuppression in renal transplantation patients  
E. Gore  
University of Groningen, The Netherlands
- O12** Cytomegalovirus (CMV)-Specific Polyfunctional T-Cell Responses after Liver Transplantation (LT) quantified by Intracellular Cytokine Staining (ICS)  
F.X. López-Labrador  
Conselleria de Sanitat & Instituto De Salud Carlos III, Spain

## 17.30 - 18.45 Session 3 Prevention / Vaccines

Chair: Peter Coyle, Athanasios Tsakris

## 17.30 - 18.00 Keynote Lecture

Vaccination - challenges in realizing their potential  
Mike Catchpole (ECDC)

## 18.00 - 18.45 Oral Presentations

- O13** Persistent systemic rotavirus vaccine infection in a child with X-linked SCID  
T. Yoshikawa  
Fujita Health University, Japan
- O14** Antiviral activity of Brincidofovir against Parvovirus B19  
G. Gallinella  
University of Bologna, Italy
- O15** Measles virus genotyping reveals two importations events during the measles outbreak (2017-8) in Greece.  
E. Horefti  
Hellenic Pasteur Institute, Greece

## 18.45 - 19.45 Industry-Sponsored Symposium

## 19.45 - 20.45 Opening Ceremony - Welcome Addresses

Prof. George Sourvinos, Chair of the 21<sup>st</sup> ESCV Annual Meeting  
Prof. Javier Buesa, President of ESCV  
Mrs Maria Stratigaki, Vice Mayor of the City of Athens  
Mrs Elena Kountoura, Minister of Tourism

## Opening Lecture

Prof. Harald zur Hausen (Nobel Laureate)  
Prevention of Cancer: the Perspective of Identifications of Cancer-Linked Infections

## 20.45 Welcome Reception



# Scientific Programme

08.30 - 09.30 **Industry-Sponsored Symposium**

09.30 - 10.30 **Session 4  
Viral Pathogenesis and Immune Responses**

Chair: Hans Hirsch, Mariet Feltkamp

09.30 - 10.00 **Keynote Lecture**

Using novel viruses and proteomics to understand the interaction between HCMV and the immune system  
Richard Stanton (UK)

10.00 - 10.30 **Oral Presentations**

**O16** Determining the mechanism of transport and excretion of Epstein-Barr virus encoded small RNAs from infected cells

G. Khan

United Arab Emirates University, United Arab Emirates

**O17** Identification of an NK inhibitory function by an HCMV protein of the RL11 family

V.M. Vlachava

Cardiff University, United Kingdom

**O18** Effect of viral genetic variability in Hepatitis C virus pathogenesis

I. Karakasiliotis

Democritus University of Thrace, Hellenic Pasteur Institute, Greece

10.30 - 11.00 **Coffee Break**

11.00 - 12.30 **Session 5  
Emerging Viruses**

Chair: Marcus Panning, Heli Harvala

11.00 - 11.30 **Gardner Lectureship**

Emerging arboviruses in the Mediterranean region  
Anna Papa (Greece)

11.30 - 12.30 **Oral Presentations**

**O19** Cutavirus DNA in skin of cutaneous T-cell lymphoma and organ transplant patients but not in healthy adults

M. Söderlund-Venermo

University of Helsinki, Finland

**O20** Development of *ex-vivo* ELISpot assay for the evaluation of DENV-specific T-cell response

I. Cassaniti

Fondazione IRCCS Policlinico San Matteo, Italy

**O21** Diseases transmitted by *Aedes spp.* mosquitoes - Urgent prevention and response measures in Greece

A. Vakali

Hellenic Center for Disease Control and Prevention, Greece

**O22** Severe encephalitis caused by mammalian 1 bornavirus

K. Korn

Universitätsklinikum Erlangen, Germany

12.30 - 14.00 **Lunch**

**ESCV Council Meeting (including lunch)**

14.00 - 15.00 **Industry-Sponsored Symposium**

15.00 - 16.00 **Industry-Sponsored Symposium**

16.00 - 17.30 **Session 6  
Hepatitis Viruses**

Chair: Anne-Marie Roque-Afonso, Susanne Gjeruldsen Dudman



## Scientific Programme



Monday 24<sup>th</sup> September 2018

16.00 - 16.30	<b>Keynote Lecture</b> HEV infection in Europe Jacques Izopet (France)
16.30 - 17.30	<b>Oral Presentations</b>
	<b>O23</b> Prevalence of Occult Hepatitis B infection in chronic hepatitis C and Cryptogenic hepatitis Patients B. Çakal Istanbul University, Turkey
	<b>O24</b> Evaluation of the detection and quantification of HBV RNA in serum as a potential biomarker in HBeAg-negative chronic hepatitis B virus (HBV) infection E. Hadziyannis National and Kapodistrian University of Athens, Greece
	<b>O25</b> Hepatitis E infection in solid organ transplant recipients in Turkey A.A. Sayiner Dokuz Eylul University, Turkey
	<b>O26</b> Hepatitis E infection as a secondary condition in hepatitis C patients and as a possible risk factor in the development of hepatocellular carcinoma C. Crossan Glasgow Caledonian University, UK
17.30 - 18.00	<b>Coffee Break</b>
18.00 - 19.30	<b>Session 7</b> <b>Congenital &amp; Neonatal Viral Infections</b> Chair: Pamela Vallely, Andreas Mentis
18.00 - 18.30	<b>Keynote Lecture</b> New Aspects in prenatal and postnatal CMV infection Klaus Hamprecht (Germany)
18.30 - 19.30	<b>Oral Presentations</b>
	<b>O27</b> Functional impairment of CMV-reactive cellular immunity during pregnancy L. Deml Lophius Biosciences GmbH, Germany
	<b>O28</b> Prolonged Parvovirus B19 DNAemia in pregnant women: Prevalence, comprehensive serological analysis and fetal complication risk L. Weseslindtner Medical University of Vienna, Austria
	<b>O29</b> Cytomegalovirus DNAemia in Pregnant Women with High IgG Avidity Index; is it a Valuable Tool for Diagnosing Nonprimary Infections? I. Karageorgou Hellenic Pasteur Institute, Greece
	<b>O30</b> Clinical, neuroimaging and audiological findings in young infants with congenital cytomegalovirus infection referred at neonatal hearing screening. A. Vossen Leiden University Medical Center, The Netherlands
19.30 - 21.00	<b>Poster Session (P001-P158)</b>



# Scientific Programme

08.30 - 09.30 **Industry-Sponsored Symposium**

09.30 - 10.30 **Session 8**  
**Diagnostic Advances in Clinical Virology I / Point-of-Care Diagnostics**

Chair: Annemiek van der Eijk, Nikos Spanakis

09.30 - 10.00 **Industry Lecture Award**

The virology lab of the future: Impact of Point of Care diagnostics  
Eric Claas (The Netherlands)

10.00 - 10.30 **Oral Presentations**

**O31** Rapid influenza A/B and RSV testing to improve outbreak management in long-term and acute care facilities

C. Lowe

Providence Health Care & University of British Columbia, Canada

**O32** Interpretation software: is there an added value for users of in-house multiplex real time PCR based diagnostics?

K. Dierickx

OLVZ Aalst, Belgium

**O33** Evaluation of Panther Fusion® Respiratory kit in a hospitalized population

M. Pichon

Infectious Agents Institute & National Reference Center for Respiratory Viruses, France

10.30 - 11.00 **Coffee Break**

11.00 - 12.30 **Session 9**  
**Viral Gastroenteritis / CNS infections**

Chair: Javier Buesa, Alexandra Valsamakis

11.00 - 11.30 **Keynote Lecture**

Taking gastro-surveillance into 21<sup>st</sup> century  
Thea Kølsen Fischer (Denmark)

11.30 - 12.30 **Oral Presentations**

**O34** Etiology of Gastrointestinal Pathogens Causing Acute Gastroenteritis in Children from Kansas City, USA, 2011 to 2016

R. Selvarangan

Children's Mercy & University of Missouri-SOM, USA

**O35** High viral shedding in hospitalized patients infected with emerging recombinant norovirus GII.P16-GII.2

S.K.C. Cheung

The Chinese University of Hong Kong, China

**O36** Genetic diversity of noroviruses circulating in longitudinal birth cohorts in low-resource countries

J. Vinjé

CDC, USA

**O37** Emergence of rotavirus G12 in a neonatal intensive care unit in Ankara

A. Altay-Kocak

Baskent University, Turkey

12.30 - 13.30 **Lunch - Poster Session (P159-P318)**

**European Network for Non-Polio Enteroviruses (ENPEN)**

Update to the collaborative activities

Heli Harvala and Thea Kølsen Fischer

13.30 - 14.30 **Industry-Sponsored Symposium**

14.30 - 15.30 **Industry-Sponsored Symposium**

## Scientific Programme



Tuesday 25<sup>th</sup> September 2018

**15.30 - 16.40 Session 10**  
**HIV / Sexually transmitted viral infections**

Chair: Svein Arne Nordbø, Elizaveta Padalko

**15.30 - 15.55 Keynote Lecture**

Human Antibodies in the treatment of viral infections  
Florian Klein (Germany)

**15.55 - 16.40 Oral Presentations**

**O38** How can next generation sequencing improve the surveillance of transmitted antiretroviral resistance?

J. Fonager

Statens Serum Institut, Denmark

**O39** Adenosine causes read-through into the late region of the HPV16 genome in a guanosine-dependent manner

H. Yu

Lund University, Sweden

**O40** "All-in-One" HIV-1 *pol*-PCR and Next-Generation-Sequencing for the analysis of drug resistant HIV-1 *pol* quasiespecies

N. Lübke

Heinrich-Heine University, Germany

**16.40 - 17.05 Coffee Break**

**17.05 - 18.15 Session 11**  
**Diagnostic Advances in Clinical Virology II / Clinical Metagenomics**

Chair: Hubert Niesters, Randall Hayden

**17.05 - 17.30 Keynote Lecture**

Metagenomics for pathogen detection in encephalitis  
Judith Breuer (UK)

**17.30 - 18.15 Oral Presentations**

**O41** Genotyping of enterovirus and adenovirus using next generation amplicon sequencing discloses frequent infections with two virus strains in children from the Norwegian MIDIA study

O. Cinek

Charles University, Czech Republic

**O42** Results from metagenomic sequencing of clinical samples during 2016-2018

M. Lind Karlberg

Public Health Agency of Sweden, Sweden

**O43** Implementing Next Generation Sequencing to Enhance Virological Surveillance of Influenza during the 2017/18 Season in Wales

C. Moore

Wales Specialist Virology Centre, United Kingdom

**18.15 - 18.35 ESCV General Assembly**

**18.40 Departure for the Greek Night Dinner**





# Scientific Programme

08.30 - 09.30 **Industry Sponsored Symposium**

09.30 - 11.00 **Session 12**  
**Viral Oncogenesis**

Chair: Paul Klapper, Paulo Paixão

09.30 - 10.00 **Keynote Lecture**  
From HPV infection to carcinoma  
Stina Syrjänen (Finland)

10.00 - 11.00 **Oral Presentations**

**O44** Searching HPV genome for methylation sites involved in molecular progression to cervical precancer. Results from *E6*, *E7* and *UTR* genes  
C. Kottaridi  
National and Kapodistrian University of Athens, Greece

**O45** Human endogenous retroviruses are overexpressed and demethylated in right colon cancer tissue, and packaged in plasma extracellular vesicles of colon cancer patients  
M. Dolci  
University of Milan, Italy

**O46** Molecular characterization of human papilloma virus isolates from head and neck squamous cell carcinoma  
R. Dhodapkar  
Jawaharlal Institute of Postgraduate Medical Education and Research, India

**O47** Analysis of Human Papillomavirus (HPV) 16 E6, E7 genes and Long Control Region in cervical samples of Italian women  
M. Martinelli  
University of Milano-Bicocca, Italy

11.00 - 11.30 **Coffee Break**

11.30 - 12.00 **Industry Lecture Award**

Evolution of influenza viruses  
E. Pariani

12.00 - 13.30 **Session 13**  
**Clinical Syndromes**

Chair: Louis Kroes, Giorgio Gallinella

12.00 - 12.30 **Keynote Lecture**  
Comprehensive testing for respiratory infections - making a difference to patient pathway  
Kate Templeton (UK)

## Scientific Programme

12.30 - 13.30

### Oral Presentations

- O48** Frequency and clinical characteristics of Epstein-Barr virus (EBV), cytomegalovirus (CMV), human herpesvirus-6A (HHV-6A), HHV-6B, HHV-7 infections in children visiting emergency room (ER)  
F. Hattori  
Fujita Health University School, Japan
- O49** Fat embolism syndrome in sickle cell disease in association with acute parvovirus B19 infection  
T. Lampejo  
Guy's and St Thomas' NHS Foundation Trust, UK
- O50** Evaluating biochemical signatures of viral infections in the central nervous system  
A. Bosworth  
Public Health England, Birmingham Heartlands Hospital, UK
- O51** Detection of Parvovirus B19 DNA in Blood of Patients with Dilated Cardiomyopathy Not Compatible with Active or Recent Viral Infection  
A. Russcher  
Leiden University Medical Center, The Netherlands

13.30 - 14.00

### Closing Remarks - Hand Over

(Presentation of the 22<sup>nd</sup> ESCV Meeting)



Wednesday 26<sup>th</sup> September 2018



## Posters' Index / Poster Sessions

- P001** **In vitro inhibitory effect of pomegranate (punica granatum L.) peel extract and the correspond fractions on influenza virus replication**  
Withdrawn by the author
- P002** **Point of care testing for the detection of influenza viruses: does speed compromise analytical performance?**  
B. Vanmassenhove\*, A. Hervent, L. Persijn, L. Vynckier, G. Alliet (Oostende, Belgium)
- P003** **Fifteen years of evolution of human respiratory syncytial virus subgroup A in Normandy, France.**  
J. Moriceau, A. Vabret, J. Dina\* (Caen, France)
- P004** **The Sigma-Virocult® specimen collection system is highly compatible with molecular syndromic panel-based testing of respiratory pathogens**  
E. Xenaki\*, A. Dermitzaki, N. Malliarakis, M. Stamataki, M. Ergazaki, G. Sourvinos (Heraklion, Greece)
- P005** **Influenza activity in Izmir, Turkey, October 1, 2017-February 20, 2018**  
C. Cicek, M. Kayin, O. Altun Koroglu, E.U. Saz, F. Bacakoglu, H. Pullukcu, A. Zeytinoglu\* (Izmir, Turkey)
- P006** **Adenoviral Respiratory Infections in Singapore**  
C.C. Wong\* (Singapore, Singapore), T.T. Nguyen, K.K. Coleman, A.W.L. Wong, S.C. Ang, P.K. Kian, T.K. Cheng, K.P. Chan, G.C. Gray, J.G. Low
- P007** **Epidemiological and molecular investigation of non-seasonal influenza-related viral respiratory infections in Northern Italy during four consecutive influenza seasons (2014-2018)**  
C. Galli\*, L. Pellegrinelli, G. Anselmi, V. Primache, S. Binda, E. Pariani (Milan, Italy)
- P008** **Respiratory syncytial virus surveillance in the Czech Republic: present and future**  
L. Novakova\*, H. Jirincova, D.Trnka, R. Limberkova, J. Kyncl, A. Nagy, M. Havlickova (Prague, Czech Republic)
- P009** **Phylogenetic characterization of human rhinoviruses from infants in Sarlahi, Nepal**  
J. Kuypers\* (Seattle, WA, USA), G. A. Perchetti, H. Y. Chu, A. S. Magaret, J. Katz, S. K. Khatry, S. C. LeClerq, K. R. Jerome, J. M. Tielsch, M. C. Steinhoff, J. A. Englund
- P010** **Detection and Characterisation of Measles Virus in Ireland 2017/2018**  
Tuite G.\*, Neary M., Cotter S., Ronayne A., De Gascun CF., Connell J. (Dublin, Ireland)
- P011** **Epidemiology of WUPyV among hospitalized children with respiratory tract infections in Beijing, China**  
L.S. Zheng\* (Beijing, China)
- P012** **Classifying viral respiratory infections through human transcriptome analysis on a rapid, easy-to-use, molecular platform**  
R. J. Crisp\* (Salt Lake City, UT, USA), C. Gritzen, T. Wilson, J. Nawrocki, M. Deneris, C. L. Baird, E. M. Ott, J. Jones, J. Bastar, H. Kim, S. House, D. Cohen, A. Leber, A. C. Hemmert
- P013** **Presence of respiratory viruses in ICU patients with community acquired-pneumonia (CAP): a one-year retrospective single center study**  
M. Giry, B. Misset, D. Boyer, A. Baron, L. Lemée, J.C. Plantier, M. Gueudin\* (Rouen, France)
- P014** **Estimating the burden of human coronaviruses during the last 5 seasons at National Influenza Centre Slovenia**  
N. Berginc\*, K. Prosenc (Maribor, Slovenia)
- P015** **Antiviral effect of an essential oil derived from three aromatic plants against viruses causing infections of the upper respiratory system**  
M. Tseliou\* (Heraklion, Greece), SA. Pirintsos, C. Lionis, E. Castanas, G. Sourvinos
- P016** **Unexpected dominance of influenza type B during the 2005/2006 and 2017/2018 epidemic seasons in the Czech Republic**  
M. Havlickova, H. Jirincova, D. Trnka\*, J. Kyncl, R. Limberkova, L. Novakova, A. Nagy (Prague, Czech Republic)
- P017** **Comparison of throat swabs, oral fluid collection devices (Oracol) and FTA® cards for the molecular detection and genotyping of measles virus**  
B. Bankamp\* (Atlanta, GA, USA), C. Sein, E. Pukuta Simbu, R. Anderson, E. Abernathy, M. Chen, K.A. Wannemuehler, D. Waku, E.N. Lopareva, J. P. Icenogle, P.A. Rota, J.L. Goodson
- P018** **Molecular detection of fifteen respiratory viruses in hospitalized children - first year results of four-year prospective study from Croatia**  
S. Ljubin-Sternak\* (Zagreb, Croatia), I. Ivković-Jureković, M. Mijac, I. Kale, D. Slacanac, B. Kolarić, A. Lukić-Grlić, J. Vraneš
- P019** **Etiology and seasonality of viral respiratory tract infections in Antalya, Turkey**  
O.M. Parkan\* (Antalya, Turkey), A.E. Daloglu, B.O. Peker, I. Saglik, O. Koyuncu Ozyurt, D. Mutlu, D. Colak
- P020** **Investigation of respiratory infections**



## Posters' Index / Poster Sessions



- with the film Array RP in adults and children  
G. Chronopoulou\*, C. Vossou, A. Kouki, E. Pagonidou (Athens, Greece)
- P021** **Rapid detection of respiratory pathogens with the ePlex multiplex platform**  
T. Chane-Teng\* & L. Avramis\*, C. Dimeglio, J. Izopet, C. Mengelle, J-M Mansuy (Toulouse, France)
- P022** **Biennial outbreak pattern of enterovirus D68 in Norway**  
J.L. Dembinski\* (Oslo, Norway), N. Milhano, A. Christensen, A.M.B. Kran, T. Kofstad, N.E. Nyquist, T.B Riste, U. Houge, S.H. Hartzen, N. Grude, S. Dudman
- P023** **Development and characterization of an Aerodynamicsystem for pulmonary delivery of Influenza vaccine**  
Withdrawn by the author
- P024** **Respiratory Syncytial Virus Genotypes Circulating Amongst Children and Elderly in Slovenia**  
N. Volmajer\*, M. Cimerman, B. Blažič, K. Soršak, A. Golle, D. Duh (Maribor, Slovenia)
- P025** **UK NEQAS Microbiology: First year review of the Molecular Detection of Respiratory viruses EQA scheme**  
S. Whitmore\*, B. Kele, E. Elenoglou, H. Seyedzadeh, and S. Rughooputh (London, UK)
- P026** **Genetic characterization of respiratory syncytial virus circulating in Lyon, France, between 2010 and 2018**  
A. Gaymard\*, M. Pichon, D. Barthelemy, Q. Semanas, B. Simon, S. Etievant, E. Frobert, M. Valette, M. Bouscambert, G. Billaud, JS. Casalegno, B. Lina, L. Josset, F. Morfin (Lyon, France)
- P027** **Production of a quality control reagent for the molecular detection of Enterovirus D-68**  
C. Santirso-Margaretto\*, M. Madjumar, T. Wilton, B. Valdazo Gonzalez, J. Martin, R. Anderson and N. Almond (Hertfordshire, UK)
- P028** **Evaluation of geneLEAD VIII (GLVIII) system for viral respiratory infections**  
M. Pichon\*, A. Balandine, M. Valette, G. Billaud, B. Lina, F. Morfin (Lyon, France)
- P029** **Entero/rhinovirus species in respiratory samples in Belgium in 2017**  
E. Wollants, A. Rector\*, E. Keyaerts and M. Van Ranst (Leuven, Belgium)
- P030** **Predominance of nonrecombinant and recombinant CV-A6 related to hand, foot and mouth disease and herpangina at primary care centers (Barcelona, Spain) during the 2017-2018 season**  
C. Andrés\*, P. Fernandes, M. Piñana, L. Gimferrer, E. Guasch, D. Van Esso, MG. Codina, J. Esperalba, MC. Martín, F. Fuentes, S. Rubio, T. Pumarola, Group for EV Surveillance in Paediatric Primary Care, A. Antón (Barcelona, Spain)
- P031** **Incidence of respiratory viruses in a tertiary hospital of the north of Spain**  
M. Larrea Ayo, M. Gallego Rodrigo, P. Iraurgi Arcarazo, O. Martínez Expósito, I. Martínez Rienda, J. Escudero Argaluz, M. Sota Busselo, M. Aranzamendi Zaldumbide\* (Barakaldo, Spain)
- P032** **Human metapneumovirus: are the new duplications within the G gene responsible for doubling its prevalence?**  
M. Piñana\*, C. Andrés, L. Gimferrer, MG. Codina, MC. Martín, J. Esperalba, F. Fuentes, S. Rubio, P. Alcubilla, T. Pumarola and A. Antón (Barcelona, Spain)
- P033** **Analytical and clinical validation of the Fast Track Diagnostics FLU/HRSV test.**  
J. Breyne\*, R. De Smedt, S. Vervaeke (Roeselare, Belgium)
- P034** **Human Parechoviruses in Children with AFP and Asymptomatic Children**  
I. Karageorgou\*, V. Poga, V. Labropoulou, A. Voulgari-Kokota, M. Emmanouil, A. Mentis (Athens, Greece)
- P035** **Active Surveillance of Influenza Viruses in Children with Influenza-like-illness in 2017-2018 Influenza Seasons**  
Withdrawn by the author
- P036** **Genetic variability of the fusion protein and circulation patterns of the respiratory syncytial virus in Spain (2013-2018)**  
L. Gimferrer, M. Piñan, C. André, G. Chavarria-Mir, M. Gema Codin, MC. Martí, J. Esperalb, F. Fuente, S. Rubi, T. Pumarol, and A. Antón\* (Barcelona, Spain)
- P037** **Respiratory pathogens detected by multiplex PCR in an university hospital**  
R. Can Sarinoglu\*, B. Aksu, G. Söyletir (Istanbul, Turkey)



## Posters' Index / Poster Sessions

- P038** **Phylogenetic Analysis of Mumps SH Sequences from Clinical Specimens in the United States: 2015 - 2017**  
R.J. McNall\* (Atlanta, GA, USA), A.K. Wharton, R. Anderson, E.N. Lopareva, J.K. Hacker, A. Strain, P.W. Bryant, K. St George, P. Shult, N. Clemmons, B. Bankamp, C.J. Hickman, K. Bradley, and P.A. Rota
- P039** **Respiratory Syncytial Virus infection in southern Brazil: a possible new BA genotype**  
H.I.G. Giamberardino\*, S.M. Raboni, J.Stadinicki, M.C. Debur (Paraná, Brazil)
- P040** **Assessing the utility of routine respiratory virus testing in managing adult cystic fibrosis (CF) patients**  
Withdrawn by the author
- P041** **Factors affecting compliance with tuberculosis treatment in Pakistani people**  
Withdrawn by the author
- P042** **Biomolecular characteristics properties of human influenza A(H1N1) Virus in Kazakhstan**  
Klivelyeva N.\*, Glebova T., Shamenova M., Lukmanova G., Saktaganov N., Ongarbaeva N., Kalkozhaeva M., Baymuhametova A., Baiseit S. (Almaty, Republic of Kazakhstan)
- P043** **The impact of molecular point-of-care testing for respiratory viruses: further analysis from a large pragmatic randomised controlled trial**  
Withdrawn by the author
- P044** **Clinical characteristics associated with Respiratory Syncytial Virus in children hospitalized with acute respiratory tract infection**  
B. Manuel\*, C. Ihling, S. Schnee, R. Peters, J. Hoos, J. Tabatabai, P. Schnitzler, J. Pfeil (Heidelberg, Germany)
- P045** **Striking difference between children and adults in prevalence of Influenza A and B during the 2017-2018 influenza season in Belgium**  
A. Vankeerberghen\*, K. Dierickx, A. Boel, L. Cattoir, K. Van Vaerenbergh, H. De Beenhouwer (Aalst, Belgium)
- P046** **A high throughput robust platform for respiratory pathogen detection using TaqMan and OpenArray technologies**  
A.J. Chmura\*, I. Pagani\*, P. Brzoska, K. Li, D. Keyes, N. Fantin, S. Patel, B. Huang, J. Li, E. Zeringer, N. Puri, K. Varma (South San Francisco, CA, USA)
- P047** **Evaluation of Alere™ i for rapid detection of RSV and influenza A&B compared to a multi-parameter customized respiratory TaqMan® array card**  
A. Muyldermans, P. Descheemaeker, M. Reynders\* (Bruges, Belgium)
- P048** **Retrospective epidemiological study of respiratory tract infections in children using Automated Multianalyte Maripoc System (AMMS)**  
C. Vossou, A. Kouki, M. Zafeiropoulou, G. Chronopoulou\* (Athens, Greece)
- P049** **Antibody binding Vs non-antibody binding regions: comparison of mutation rate in A(H3N2) viruses**  
A. Kossyvakis\* (Athens, Greece), V. Pogka, A. Kalliaropoulos, I. Karagiannis, E. Antalis, S. Tsiodras, T. Lytras, A. F. Mentis
- P050** **Viral genomic diversity of influenza virus in a retrospective cohort of pregnant women in Lyon, France**  
G. Destras\*, M. Pichon, B. Simon, M. Valette, A. Bal, V. Escuret, P. Gaucherand, P.A. Bolze, B. Lina, L. Josset (Lyon, France)
- P051** **Incorporating whole-genome next-generation sequencing (NGS) to Influenza virus surveillance in Public Health**  
F.X. López-Labrador\* (Valencia, Madrid, Spain), L. Cano, M.M. Mosquera, P. de Molina, R. Vendrell, G. d'Auria, L. Martínez-Priego, J. Díez-Domingo, M. Jané, N. Torner, A.I. Martinez, J. Vila, M.A. Marcos
- P052** **Improved patient diagnosis with multiplex respiratory pathogen testing: Closing the diagnostic gap**  
A. Waters\*, D. Waldron, O. Loughlin, C. De Gascun (Dublin, Ireland)
- P053** **Molecular epidemiology of respiratory syncytial virus in children, Greece 2016-2018**  
S. Pappa\*, K. Tsergouli, M. Gogou, K. Haidopoulou, A. Papa (Thessaloniki, Greece)
- P054** **Influenza virus type/subtype and different infection profiles by age group during 2017/2018 season.**  
R. Guiomar\*, Portuguese Laboratory Network for the Diagnosis of Influenza Infection (Lisbon, Portugal)
- P055** **Virological surveillance of influenza B viruses during 2017/18 influenza season and the newly emergent B/Victoria lineage variant in the European Union/European Economic Area (EU/EEA) countries**  
A. Melidou\*, C. Adlhoch, R. Snacken, P. Mooks, D. Pereyaslov, P. Penttinen, European region influenza surveillance network (ECDC, WHO)
- P056** **Evaluation of the analytical performances of the HHV6 R-GENE® assay (ARGENE®, bioMérieux)**

## Viruses in the immunosuppressed host

- P056** **Evaluation of the analytical performances of the HHV6 R-GENE® assay (ARGENE®, bioMérieux)**

## Posters' Index / Poster Sessions

- A. Turc\* (Grenoble, France), C. Arlaud, C. Kappler, D. Kulifaj, M. Muntaner, C. Vidal, A. Derome, F. Gelas, M. Joannes
- P057** **Interest of using Validation Manager™ (Finbiosoft) in comparative studies: case of performance validation of HHV6 R-GENE® and CMV R-GENE® assays (ARGENE®, bioMérieux) on four amplification platforms.**  
J. Bourdin\* (Grenoble, France), C. Drevet, A. Turc, C. Arlaud, C. Kappler, A. Derome, Gelas A.F., M. Joannes, T. Hirvonen, A. Virtanen
- P058** **Production of multivirus specific T cells for treatment of immunosuppressed patient after hematopoietic stem cells transplantation**  
S. Nemeckova\*, J. Krystofova, P. Hainz, J. Musil (Prague, Czech Republic)
- P059** **Recombinant phenotyping of herpes simplex virus UL23 thymidine kinase sequence variants for acyclovir resistance**  
D. Boutolleau\*, T. Goupil-Gouyette, R. Bellone, J. Marlet, S. Burrel (Paris, France)
- P060** **Trends in herpes simplex virus resistance to antivirals over the last decade in France**  
S. Burrel\*, O. Roger, J.C. Piot, M. Thévenin, F. Mousnier, L. Hermet, D. Boutolleau (Paris, France)
- P061** **Varicella-zoster virus resistance to antivirals: results from a 9-year survey in France**  
D. Boutolleau\*, O. Roger, J.-C. Piot, M. Thévenin, F. Mousnier, L. Hermet, S. Burrel (Paris, France)
- P062** **Comparison of whole blood and plasma for detection of cytomegalovirus DNA in transplant patients.**  
L. Duus\*, K. Handberg, S. Ellermann-Eriksen (Aarhus, Denmark)
- P063** **Investigation of EBV infection in patients with acute lymphoblastic leukemia and lymphoma**  
M. Colak, S. Sarzhanova, Z.N. Ozkurt, Z.A. Yegin, I. Fidan, K. Caglar, G. Bozdayi\* (Ankara, Turkey)
- P064** **Investigation of JCV positivity in patients with bone marrow transplant**  
M. Colak, A. Altay-Kocak\* (Ankara, Turkey), H. Muftah, Z. N. Ozkurt, Z. A. Yegin, G. Bozdayi
- P065** **Development of a Combined CMV-UL97 C592F and CMV-UL54 T503I Resistance Mutation during Prophylactic Ganciclovir Treatment in a Kidney Transplant Recipient**  
M. Karrasch\*, D. Michel, S. Schneider, M. Baier, M. Busch (Jena, Germany)
- P066** **QuantiFERON® - CMV Gamma Interferon - releasing Assay as an Early Diagnostic Predictor for Late Phase Cytomegalovirus Infection following Kidney Transplantation**  
M. Karrasch\*, S. Schneider, M. Baier, M. Busch (Jena, Germany)
- P067** **When EBV serology needs a blot to conclude**  
E. Perillaud-Dubois\*, E. Bouthry, I. Kounis, A.-M. Roque-Afonso, C. Vauloup-Fellous (Villejuif, France)
- P068** **Seroprevalence of Cytomegalovirus in hemodialysis patients**  
A. Bakossi\*, M. Demetriou, I. Daniil, N. Zachos, T. Peppas, P. Karle (Athens, Greece)
- P069** **Detection of cytomegalovirus DNA in bone marrow transplant recipients by quantitative real time pcr**  
I. Fidan, Z. Koc\*, G. Bozdayi, Z.N. Ozkurt, L. Kaynar, F. Can (Ankara, Turkey)
- P070** **Stability of nucleic acid in various specimen types for molecular applications: case of ARGENE® product (bioMérieux)**  
V. Monnot\*, N. Beaufet, K. Chiazza, S. Moutin, M. Muller, A. Perrod, M. Joannes (Grenoble, France)
- P071** **Cytomegalovirus infection in non-immunocompromised critically ill patients**  
H. Naija\*, W. Sellemi, Z. Hajje, M. Amara, M. Ferjani, M. Ben Moussa (Tunis, Tunisia)
- P072** **Validation of the cobas® 4800 CMV assay on bronchoalveolar lavage samples**  
J. Breyne\*, S. Vervaeke (Roeselare, Belgium)
- P073** **Investigation of BK Virus DNA Positivities by Real-Time PCR in Immunosuppressive Patients**  
H. Muftah\*, A. Kocak-Altay, S. Yigit, K. Yuce, G. Bozdayi (Ankara, Turkey)
- P074** **Comparison of two commercial quantitative Cytomegalovirus PCR tests**  
Withdrawn by the author
- P075** **Distribution of torque teno virus DNA in the cellular fractions of the**







# Posters' Index / Poster Sessions

## bronchoalveolar lavage of lung transplant patients

I. Görzer\*, C. Lambers, A. Popovitsch, D. Bajons, M. Segura-Wang, N. Perkmann-Nagele, J. Aberle, E. Puchhammer-Stöckl (Vienna, Austria)

- P076** **Comparison of a new quantitative real-time PCR assay (HHV6 R-GENE®, ARGENE®, BioMérieux) to the CMV HHV6,7,8 R-GENE® assay for detection and quantification of Human Herpes Virus 6 (HHV-6) DNA in various clinical specimens**

A. Larivière, P. Magnier, C. Chessa, A. Bourgoïn, N. Lévêque, A. Gautheret-Dejean, A. Beby-Defaux\* (Poitiers, France)

- P077** **The Assessment of Laboratory Performance in the Molecular Detection of Transplant-Associated Pathogens Through International EQA Testing**

L. O'Donnell, E. McCulloch\* (Glasgow, UK), P.S. Wallace, H.G. Niesters

- P078** **Prevalence of BKPyV genotypes in kidney transplant recipients**

M. Salakova\* (Prague, Czech Republic), M. Wohlfahrtová, M. Fajfr, K. Klečáková, V. Šroller, R. Tachezy

- P079** **Quantitative PCR for monitoring polyomavirus BK infection in kidney transplantation**

T. Trujillo-Soto, J. Arca-Suarez, I. Guerrero-Lozano, F. Galan-Sanchez, M. Rodriguez-Iglesias\* (Cadiz, Spain)

- P080** **HCMV pUL105 helicase, a promising antiviral target**

G. Ligat, S. Alain\*, S. Hantz (Limoges, France)

- P081** **New approaches for quantitative EBV DNA monitoring of transplant patients and patients with EBV-associated malignancies.**

M.K. Thomsen\*, P. Böttger, S. Ellermann-Eriksen, L.U.P. Ludvigsen, K. Jensen-Handberg (Aarhus, Denmark)

- P082** **Limitations and usefulness of CMV serological markers in transplanted patients**

D. Alexandrova\*, D. Ilin, Y. Petrov, B. Spassov (Sofia, Bulgaria)

- P083** **Clinical validation of a novel ELISpot-based in vitro diagnostic assay to monitor CMV-specific cell-mediated immunity in immunocompromised transplant recipients**

B. Banas, D. Steubl, L. Renders, D. Chittka, M. C. Banas, T. Wekerle, M. Koch, O. Witzke, M. Lindemann, A. Mühlfeld, C. Sommerer, A. Habicht, C. Hugo, T. Hünig, S. Mielke, M. Schreder, E. Wagner, D. Teschner, S. Klein, D. Heidenreich, S. Kreil, K. Schäfer-Eckart, J. Gärtner, M. Verbeek, S. Graß, C. Wolschke,

D. Janson, G. Kobbe, M. Kondakci, M. Ditschkowski, T. Gromke, I. Hilgendorf, M. von Lilienfeld-Toal, T. Schmidt, A. Rasclé, S. Barabas, L. Deml\* (Regensburg, Germany), R. Wagner, B.K. Krämer, B. Krüger, D. Wolff

- P084** **Human herpesvirus 6B infection in pediatric hematopoietic stem cell transplant (HSCT) recipients**

H. Miura\*, Y. Kawamura, F. Hattori, K. Kozawa, M. Tanaka, K. Kudo, M. Ihira, H. Yatsuya, T. Yoshikawa (Toyoake, Japan)

- P085** **Human cytomegalovirus viruria in hematopoietic stem cell transplant recipients: context and impact.**

J. Node, L. Puget, A. Berceanu, A. Overs, A. Coaquette, J.L. Prétet, E. Deconinck, Q. Lepiller\* (Besançon, France)

- P086** **Origin and pattern of Human Polyomaviruses replication after kidney transplantation: a 9-months prospective observational study**

S. Villani, E. Favi, C. Colico, M. Dolci, P. Ferrante, A. Giussani, R. Ticozzi, L. Clementoni, C. Alfieri, P. Messa, M. Ferraresso, S. Delbue\* (Milan, Italy)

- P087** **Can the QuantiferonCMV assay distinguish which patients post-HSCT with CMV viraemia need treatment?**

Li KK\*, Clark A., Suarez N., Davison A., Aitken C. (Glasgow, UK)

- P088** **The prevalence of viral esophagitis in children**

M. Bordea, A. Pirvan, L.M. Junie\* (Cluj-Napoca, Romania)

- P089** **Nadir CD4+ T-cell count predicts infectious risk in kidney transplant recipients**

I. Cassaniti\*, M. Degli Antoni, K.M.G. Adzasehoun, M. Prestia, G. Comolli, M. Gregorini, F. Baldanti (Pavia, Italy)

- P090** **Chronic infection with novel GII.P26-GII.26 norovirus in an immunocompromised patient**

C. Pietsch\*, N. Ennuschat, S. Härtel, U.G. Liebert (Leipzig, Germany)

- P091** **Temporal dynamics of the lung and plasma viromes in lung transplant recipients**

M. Segura-Wang\*, I. Görzer, P. Jaksch, E. Puchhammer-Stöckl (Vienna, Austria)

- P092** **Progressive Multifocal Leukoencephalopathy (PML) in immunocompetent patient secondary to Carbamazepine - induced hypogammaglobulinaemia**

A. Khan\*, N. Elsakka (Aberdeen, UK)

- P093** **Adoptive immunotherapy as a new therapeutic perspective for patients who underwent allogeneic stem cells transplantation**

## Posters' Index / Poster Sessions

- G. Destras\*, S. Ducastelle, A. Gaymard, B. Lina, F. Morfin, F. Ader, E. Frobert (Lyon, France)
- P094** **Using a rabbit model to understand the biology of EBV infection and associated pathology in immunocompromised host**  
G. Khan\*, A. Hassani, N. Reguraman, P. Philip (Al Ain, United Arab Emirates)
- P095** **Human CMV antiviral resistance mutation detection: diagnostic application in the setting of bone marrow transplantation in pediatric patients**  
M. Emmanouil\*, A. Paisiou, I. Peristeri, S. Grafakos, A. Mentis (Athens, Greece)
- P096** **BK polyomavirus serotyping using a Luminex bead-based multiplex immunoassay**  
H.F. Wunderink, C.S. van der Blij-de Brouwer, E. van der Meijden, D.V. Pastrana, H.L. Zaaijer, A.C.M. Kroes, C.B. Buck, M.C.W. Feltkamp\* (Leiden, the Netherlands)
- P097** **In-vitro comparison of antiviral agents against major human dsDNA viruses: A systematic literature review**  
R.F. Chemaly\* (Houston, TX, USA), J.A. Hill, S. Voigt, K. Peggs
- P098** **Additional N-Glycosylation sites in HBV surface antigen characterizes immunosuppression-driven HBV reactivation and alter HBsAg recognition in vitro**  
R. Salpini, L. Piermatteo\* (Rome, Italy), A. Battisti, L. Colagrossi, M. Aragri, L. Fabeni, A. Bertoli, C. Mastroianni, M. Marignani, S. Maylin, C. Delaugerre, F. Morisco, N. Coppola, A. Marrone, N. Iapadre, M. Angelico, L. Sarmati, M. Andreoni, J. Verheyen, F. Ceccherini-Silberstein, M. Levvero, C. F. Perno, L. Belloni, V. Svicher
- P099** **Detection of VZV DNA in serum collected from pediatric acute lymphoblastic leukemia patients during chemotherapy**  
K. Kozawa\*, H. Miura, F. Hattori, M. Ihira, T. Yoshikawa (Fujita, Japan)
- P100** **Seroprevalence of fourteen human polyomaviruses determined in blood donors**  
S. Kamminga, P.Z. van der Meijden, M.C.W. Feltkamp\* (Leiden, The Netherlands), H.L. Zaaijer
- P101** **HCMV-specific T-cell immune response**

### among kidney transplant recipients (KTRs) measured at pre-transplant

I. Cassaniti\* (Pavia, Italy), F. Sidoti, K.M.G. Adzasehoun, A. Curtoni, L. Vizio G. Comolli, C. Costa, R. Cavallo, F. Baldanti

- P102** **Adenoviruses in immunocompromised paediatric patients in Faculty Hospital Motol: an outbreak of adenovirus A31 revealed by whole genome sequencing**  
L. Kramná\*, A. Briksí, P. Hubáček, O. Cinek (Prague, Czech Republic)
- P103** **Hemorrhagic cystitis as a complication after allogeneic hematopoietic stem cell transplantation – a single center experience**  
V. Vasilyeva, E. Parovichnikova, M. Drovkov, L. Kuzmina, G. Klyasova, D. Tikhomirov, T. Tupoleva, E. Domonova, S. Matosova, O. Shipulina, O. Koroleva\*, D. Dubnyak, E. Mikhaltsova, N. Popova, Z. Konova, V. Savchenko and CIC 930 (Moscow, Russian Federation)
- Prevention / Vaccines**
- P104** **Knowledge about vaccination against human papillomavirus (HPV) among Greek female adolescents**  
I.N. Mamas\* (Heraklion, Greece), M. Theodoridou, C. Koutsafiki, G. Sourvinos, D.A. Spandidos
- P105** **Monitoring of severe dengue cases and presence of adverse events after public vaccination campaign against dengue in the state of Paraná, Brazil**  
S.M. Raboni\*, H.I.G. Giamberardino, J. Cordellini, S.P.A. Paz, J.L. Crivellaro (Curitiba, Brazil)
- P106** **Environmental sampling for Norovirus GI using NRSII™ Transwab®**  
O. Maksimovic\* (Chipping Campden, UK & Gent, Belgium), M. D'Agostino
- P107** **Novel combined antigen M2e-NP-HAs is potential candidate for research and development of universal influenza vaccines**  
W. Wang\*, B. Huang, X. Wang, Y. Deng, W. Tan, L. Ruan (Beijing, China)
- P108** **Evaluation of Immunity in mice elicited by recombinant DNA-based and Non-replicating Vaccinia Virus-based Zika Vaccine candidates expressing structural proteins**







# Posters' Index / Poster Sessions

Y. Deng\*, Y. Zhan, H. Chen, WL. Wang, WJ. Tan (Beijing, China)

- P109** **Molecular characterization of RNA-protein interactions during the initiation of translation of wild-type and live attenuated mutant of Cocksackievirus B3**

J. Gharbi\* (Monastir, Tunisia)

- P110** **Cost-effectiveness of prevaccination measles screening of Health Care Workers at a Northern Greek Hospital**

A. Karyoti\*, G. Petasis, V. Pentsioglou, E. Chatzidrosou, K. Tsioni, A. Pypasopoulou, O. Tsiatsiou, E. Vagdatli (Thessaloniki, Greece)

- P111** **Analysis of the antibody specific titre for Measles viral antigens in vaccinated subjects.**

S. Semprini\*, A. Pierro, P. Schiavone, A. Denicolò, V. Sambri (Pievesestina, Italy)

- P112** **Evaluation of cellular and humoral immunity of live BIKEN varicella-zoster vaccine in adults assessed by using an interferon- $\gamma$  enzyme-linked immunosorbent assay and immune adherence hemagglutination assay (IAHA).**

A. Hata\*, A. Sakakibara, A. Hori, Y. Kobayashi, T. Watanabe, T. Katayama (Osaka, Japan)

- P113** **Measles, mumps and rubella (MMR) IgG seroprevalence in the Portuguese population, 2015-2016**

P. Palminha\*, E. Vinagre, T. Lourenço, L. Almeida, S. Moura, S. Pinto, C. Ribeiro, R. Roquette, B. Nunes (Lisbon, Portugal)

- P114** **Increase in variability of mumps virus genotype G strains in Spain, 2005-2017**

A. Fernández-García\*, A.M. Gavilán, A. Castellanos, J.C. Sanz, A. Rueda, F. de Ory, J. Masa-Calles, N. López-Perea, M. de Viarce Torres de Mier, J.E. Echevarría (Madrid, Spain)

- P115** **Rotavirus vaccines: current status and future trends**

Withdrawn by the author

- P116** **Rubella virus infections in Austria 2017**

E.M. Geringer\*, S. Aberle, D. Schmid, H. Holzmann (Vienna, Austria)

- P117** **What is the ideal HPV screening method in the oropharyngeal region? SHIO Study**

Withdrawn by the author

- P118** **Barriers for non-vaccination against human papillomavirus (HPV) among Greek female adolescents: the ELEFThERIA project**

I.N. Mamas\* (Heraklion, Greece), M. Theodoridou, C. Koutsafiki, G. Sourvinos, D.A. Spandidos

- P119** **Considerations for performance assessment and quality assurance for primary cervical screening based on molecular HPV testing**

K. Cuschieri\* (Edinburgh, UK), A. Wilson, T. Palmer, S. Coughlan

- P120** **Temporary regional eradication of rotavirus following introduction of vaccination**

C. Mansell\* (Hamilton, New Zealand)

## Viral Pathogenesis and Immune Responses

- P121** **Cytokine responses of human astrocyte and lung cell lines to several human parechoviruses**

E. Vuorinen\*, A. Siponen, A. Susi, S. Tauriainen (Turku, Finland)

- P122** **Molecular epidemiological analysis of rotaviruses obtained from rotavirus-associated encephalitis / encephalopathy patients**

M. Ihira\*, Y. Kawamura, F. Hattori, H. Miura, Y. Higashimoto, K. Sugata, S. Komoto, K. Taniguchi, T. Yoshikawa (Toyoake, Japan)

- P123** **Role of microvesicles in the viral spread of Herpes simplex type 1**

J. A. López-Guerrero\*, C. de la Nuez, B. Praena, R. Bello-Morales (Madrid, Spain)

- P124** **Acute Epstein Barr Virus Infection with Atypical Serological Profile**

I. Altuglu, A. Zeytinoglu\*, A. Donmez (Izmir, Turkey)

- P125** **Evaluation of abbot architect, siemens immulite, biomerieux vidas and euroimmune assays for determination of epstein-barr virus serological diagnosis**

O. Appak\*, M.H. Ozkaratas, A.A. Sayiner (Izmir, Turkey)

- P126** **Prevalence of DNA viruses in oral specimens**

S. Villani\*, L. Signorini, M. Dolci, M. Del Fabbro, S. Corbella, R. Ticozzi, L.A. Francetti, P. Ferrante, S. Delbue (Milan, Italy)

- P127** **Association of TAP1 gen polymorphisms in recurrent respiratory papillomatosis in population of the west of Mexico**

J. Palomares-Marín\* (Guadalajara, México), V. Araujo, L. Govea-Camacho, SY. Rodríguez-Preciado, A. Narváez, B. Ponce-Quesney, J. Morales, F. Siller-Lopez, J.F. Muñoz-Valle, I. Hernández-Cañaveral

- P128** **Evaluation of new IgM Measles assay**

T.D. Ly\*, C. Coignard (Ivry sur Seine, France)

## Posters' Index / Poster Sessions

**P129 Herpes Simplex Virus type-1 infection affects the expression of extracellular matrix components in human nucleus pulposus cells**

K. Alpantaki, A. Zafropoulos, M. Tseliou, E. Vasarmidi, G. Sourvinos\* (Heraklion, Greece)

**P130 Human Polyomaviruses other than JCPyV are found in the Cerebrospinal Fluid from patients with neurological diseases**

M. Ciotti, S. Villani, M. Dolci\* (Milano, Italy), R. Ticozzi, P. Ferrante, S. Giannella, C. Favalli, S. Delbue

**P131 Th17 cytokine profile in a study of the molecular epidemiology of respiratory viruses**

E. Antalis, A. Spathis, C. Kottaridi, A. Kossyvakis, A. Mentis, C. Kroupis, S. Tsiodras\* (Athens, Greece)

**P132 Inhibition of enveloped and non-enveloped viruses by sodium chloride: evidence of myeloperoxidase-mediated intrinsic immunity in non-myeloid cells**

H. McCaughan, T. Boote, S. Griffiths, S. Ramalingam\*, J. Haas (Edinburgh, UK)

**P133 Monitoring and Characterization of Clinical Isolates of Varicella-Zoster Virus (VZV) in Czech Republic Using Molecular Genetics Methods**

P. Bostik\*, N. Bostik and V. Bostik (Hradec Kralove, Czech Republic)

### Emerging Viruses

**P134 Guillain Barré syndrome and zika outbreak in Veracruz, México, 2016-2017**

Withdrawn by the author

**P135 Mosquito-borne viruses in Southern and Coastal Kenya**

E M. Korhonen\* (Helsinki, Finland), M. Masika, R. Uusitalo, C. Lorna Culverwell, T. Smura, A. Jääskeläinen, D. Mwaengo, O. Anzala, O. Vapalahti, E. Huhtamo

**P136 In silico strategy of an antiviral agent with therapeutic potential against Zika virus**

K. Salvatierra\* (Posadas, Argentina), M. Vera, H. Florez

**P137 Hepatitis G virus in multi-transfused individuals in N. Greece**

M. Exindari\*, P. Klonizakis, E. Vlahaki, G. Gioula (Thessaloniki, Greece)

**P138 Assay performance of a new automated Zika-IgG specific immunoassay in patients from prevalence areas**

M. Gloeck, S. Lepa, E. Stadlbauer, H. Girgnhuber, T. Laengin, A. Riedel\* (Penzberg, Germany)

**P139 Presence of human bocaviruses and parvovirus 4 genomic sequences in post mortem individuals with unspecified encephalopathy**

Z. Nora-Krukke\*, A. Vilmane, I. Sedleniece, S. Rasa, S. Roga, M. Murovska (Riga, Latvia)

**P140 Incidence and clinical relevance of human bocavirus (HBoV) infections in pediatric patients**

V. Verbeke\* (Ghent, Belgium), M. Reynders, K. Floré, S. Debulpaep, K. Sauer, F. Cardoen, E. Padalko

**P141 Increased levels of TXA2 induced by Dengue virus infection in IgM positive individuals is related to the mild symptoms of dengue**

E. S. Oliveira, S.G. Colombarolli, C.S. Nascimento, I.C.A. Batista, J.G.G. Ferreira, R.R. Assis, E.A.R. Alves, C.E. Calzavara-Silva\* (Belo Horizonte, Brazil)

**P142 Virome of californian culex mosquitoes**

R. Sadeghi\* (San Francisco, CA, USA), E. Altan, X. Deng, C. Barker, Y. Fang, L. Coffey, E. Delwart

**P143 Serological evidence of West Nile virus infection in the Portuguese population**

A.S. Ferreira, N.L. Santos-Ferreira, J.R. Mesquita, M.S.J. Nascimento\* (Porto, Portugal)

**P144 Presence of human parvovirus B19, human bocaviruses and human parvovirus 4 genomic sequences in DNA of patients with meningitis/meningoencephalitis**

A. Vilmane\*, A. Terentjeva, I. Sedleniece, S. Rasa, N. Suna, M. Murovska, Z. Nora-Krukke (Riga, Latvia)

**P145 Characterization of Viral Replication Rates of Dengue Virus Strains in Singapore**

C.C. Wong\*, K.P. Chan (Singapore, Singapore)

**P146 Emergence of variant strain of DENV 4 and 2 causing severe dengue in South India**





# Posters' Index / Poster Sessions

PFM. Sharmila\*, R. Dhodapkar (Pondicherry, India)

- P147** **External Quality Assessment (EQA) Programme for Molecular Diagnostics of Middle Eastern Respiratory Syndrome Virus (MERS) a Four Year Review**  
E. McCulloch\* (Glasgow, UK), H.G.M. Niesters, P. Wallace

- P148** **Belgian patient returning from Hungary with a confirmed West Nile Virus infection using next-generation sequencing.**  
E. Wollants\* (Leuven, Belgium), D. Smolders, R. Naesens, P. Bruynseels, K. Lagrou, J. Matthijssens and M. Van Ranst

- P149** **Whole genome sequencing of Chikungunya virus strains from two cases imported to Greece**  
A. Papa\* (Thessaloniki, Greece), E. Papadopoulou, A. Melidou, D. Pervanidou, S. Tsiodras

- P150** **West Nile Virus Nucleic Acid Testing**  
S. Kempster\*, R. Minhas, C. Morris, N. Almond (Potters Bar, UK)

- P151** **Two imported cases with hemorrhagic fever with renal syndrome**  
E. Puca\*, M. Qato, I. Koshovari, J. Majko, P. Pipero, M. Kote, D. Kraja (Tirana, Albania)

- P152** **Molecular analysis of Measles F protein to identify molecular signatures associated with neurological infections.**  
A. Piralla\*, F. Giardina, F. Rovida, F. Baldanti (Pavia, Italy)

## Viral Oncogenesis

- P153** **Clinical evaluation of the novel GeneProof HPV DNA assay**  
E. Jansová\* (Brno, Czech Republic), I. Hojsíková, P. Janda, R. Tomášová, I. Babánková, M. Sittová, M. Dendis

- P154** **Molecular analysis of the exon 19 of RB1 gene and its flanking intronic sequences in HPV16-associated precancerous lesions in the Greek population**  
M. Daskou\* (Larissa, Greece), D. Tsakogiannis, G.D. Moschonas, Z. Stylianidou, Z. Kyriakopoulou, C. Kottaridi, T.G. Dimitriou, C. Gartzonika, P. Markoulatos

- P155** **Prevalence of HPV Infection in Squamous Cell Carcinoma of the Head and Neck in Brazilian Patients**  
M.E.G. Portugal\*, M.N. Bordignon, L.R.R. Vidal, J. Jung, C.B. Ramos, G.H.A. Ramos, S.M. Raboni (Paraná, Brazil)

- P156** **Polyomaviruses SV40, BKV, and JCV infection in malignant tissues from patients with renal cell carcinoma, prostate cancer, and urinary bladder carcinoma**  
Withdrawn by the author

- P157** **Prevalence and type distribution of HPV 66 in Turkish women with and without cervical cytology abnormal**  
F. Kazanci, A. Altay-Kocak\* (Ankara, Turkey), M. Colak, M.A. Onan, G. Bozdayi

- P158** **Human Papillomavirus (HPV) DNA detection in plasma and in peripheral blood mononuclear cells (PBMCs) samples of women with cervical dysplasia**  
G. Brenna\*, M. Martinelli, A. Rizzo, C. Crotti, F. Sina, R. Musumeci, S. Chiari, F. Landoni, C. Cocuzza (Monza, Italy)

## Hepatitis Viruses

- P159** **Evaluation of a qualitative/semi-quantitative test for the detection of significant variations of HBsAg titer in monitoring patients with chronic HBV hepatitis**  
M. De Paschale\*, O. Arpino, T. Re, M.T. Manco, L. Belvisi, A. Paganini, A. Cianflone, T. Cerulli, D. Cagnin, P. Mirri, P. Viganò, P. Clerici (Milano, Italy)

- P160** **Reactivation of occult hepatitis B virus infection in patients undergoing allogeneic stem cell transplantation**  
V. Stepanova\*, L. Pliskova, M. Fajfr, A. Zavrelova, E. Vejrazkova, R. Bolehovska, S. Plisek (Hradec Kralove, Czech Republic)

- P161** **Patient tolerability of Interferon and Interferon free regimen for hepatitis C infection**  
Withdrawn by the author

- P162** **Analytical Performance and Workflow Comparisons of Multiple Molecular Platforms used for Hepatitis Viral Load Determinations**  
M. García-Álvarez, G. Areztweiler, S. Leuchter, E. Paxinos\* (Pleasanton, CA, USA), E. Marins, D. Duncan, J. Canchola, R. Delgado and A. Frontzek

- P163** **HEV Serology – The Need for Quality Control Reagents**  
F. Phimister, C. Santirso Margaretto\*, D. Padley, N. Almond (Hertfordshire, UK)

- P164** **Evaluation of HEV RNA detection in an automated Real Time PCR system by two specialized laboratories in Greece**  
G. Gioula\* (Thessaloniki, Greece), M. Sinakos, E. Gigi, E. Panopoulou, F. Spanou, E. Hadziyannis



## Posters' Index / Poster Sessions



- P165** **Determination of IL-28B polymorphism and IL-28B serum levels in Turkish patients with hepatitis B and hepatitis C**  
Z. Koc\*, E. Tug, I. Fidan (Ankara, Turkey)
- P166** **Use of Chemiluminescent Immunoassay Liaison® XL Murex Anti—HDV (DiaSorin) for Serologic Diagnosis of Hepatitis D**  
B. Rivaya, A. Velilla, R. Tenllado, N. Romani, L. Matas\* (Barcelona, Madrid, Spain)
- P167** **The changes of IL-17A and IL-23 levels in chronic hepatitis B and hepatitis C infection and their association with viral load**  
Z. Koc\*, H. Kahraman Durak, AS. Yar Saglam, A. Kalkanci, I. Fidan (Ankara, Turkey)
- P168** **Seroprevalance of HBsAg, anti-HCV and anti-HIV in patients using illicit drugs in İzmir, Turkey**  
I. Altuglu, S. Tanyeri, E. Altin Toprak, A. Zeytinoglu\* (Izmir, Turkey)
- P169** **Changing epidemiology of hepatitis c virus genotype distribution: seven-year data**  
O. Appak\*, A. Gulmez, A. A. Sayiner (Izmir, Turkey)
- P170** **Next Generation Sequencing of 5' NCR and NS5B Regions For Hepatitis C Virus Genotyping - Results From Western Part Of Turkey**  
S. Aktakka, S. Erensoy\*, H. Onay, D. Tekin, I. Altuglu, R. Sertoç (Izmir, Turkey)
- P171** **Serum Hepatitis B surface antibody (hbs-ab) levels in iranian autistic children and evaluation of immunological memory after booster dose injection in comparison with controls**  
Withdrawn by the author
- P172** **Development and Characterization of Surface Modified Chitosan Nanoparticles for Selective Targeting of Lamivudine to Hepatocyte**  
Withdrawn by the author
- P173** **Bipolymer based Novel Nanoparticles in Microsphere System as Vaccine Adjuvant**  
Withdrawn by the author
- P174** **Hepatitis E virus infection study among health individuals in bulgaria, pazardjik region**  
Withdrawn by the author
- P175** **Prognostic significance of the new criteria for acute kidney injury in HBV-related cirrhotic patients with ascites**  
C. Jin\*, S. Bi, J. Sheng (Hangzhou, China)
- P176** **Prognostic factors of mortality in acute viral hepatitis**  
E. Qyra, E. Puca\*, M. Dede, M. Qato, G. Stroni, P. Piperio, A. Harxh (Tirane, Albania)
- P177** **Serum aspartate and alanine aminotransferase levels in relation to hepatitis B and C virus infections among psychiatric patients.**  
I. Daniil\*, T. Pitsia, M. Demetriou, E. Laskos, A. Bakossi, M. Balachouti, V. Voulgaris, V. Mamakou, A. Dimitriadis, M. Dimoutsos (Athens, Greece)
- P178** **Specific HBsAg immune escape mutations correlate with increased viremia, HBsAg and ALT: potential role as enhancers of HBV pathobiology**  
R. Salpini\* (Rome, Italy), L. Piermatteo, M. Aragri, A. Battisti, V. Malagnino, A. Bertoli, M. De Cristofaro, S. Romano, R. Longo, M. Visca, L. Sarmati, C. Pasquazzi, S. Francioso, M. Ciotti, A. Spanò, G. Cappiello, M. Andreoni, M. Angelico, F. Ceccherini-Silberstein, C.F. Perno, V. Svircher
- P179** **Characterization of HBeAg levels in patients experiencing HBV-reactivation: potential role in monitoring virological response in iatrogenic immunosuppression.**  
L. Piermatteo\* (Rome, Italy), R. Salpini, A. Battisti, M. Aragri, C. Cerva, A. Bertoli, M. De Cristofaro, S. Romano, R. Longo, M. Visca, L. Sarmati, S. Francioso, A. Spanò, G. Cappiello, M. Andreoni, M. Angelico, F. Ceccherini-Silberstein, C. F. Perno, V. Svircher
- P180** **HBsAg, Anti-HBs and Anti-HCV Seropositivity Rates in Pregnant Refugee and Turkish Women**  
Withdrawn by the author
- P181** **miRNA in Hepatitis B and Hepatitis C Related Hepatocellular Carcinoma and Cirrhosis**  
Withdrawn by the author
- P182** **Description of hepatitis A outbreak-confirmed cases, France, 2016 to 2017**  
L. Mouna\*, E. Boutry, G. Decombe, A.-M. Roque-Afonso (Villejuif, France)
- P183** **Genetic Complexity of Hepatitis C Virus NS5A Epitope Positions and a Possible Association With Host Geographical Origin**



# Posters' Index / Poster Sessions

R. Alves da Silva, F. L. Kamitani, B. Vrancken, P. Lemey, I.M.V.G. de Carvalho\* (Sao Paulo, Brazil)

**P184** **Hepatitis E virus genotype 3: analysis of variability of whole coding genome**  
M. Muñoz-Chimeno, C. Polo, A. Cenalmor, L. Morago, S. Arroyo, A. Avellon\* (Madrid, Spain)

**P185** **Hepatitis A virus strains identified in the Czech Republic between the years 2007-2018**  
V. Nemecek\*, Z. Cabartova, P. Butovicova (Prague, Czech Republic)

**P186** **Analysis of clinical and epidemiological characteristics of hepatitis A and E among bulgarian patients**  
Withdrawn by the author

**P187** **Molecular epidemiology and phylogenetic analysis of hepatitis B virus in Saudi Arabia**  
A. A. Al-Qahtani\* (Riyadh, Saudi Arabia), M. R. Pourkarim, N. S. Trovão, V. Vergote, G. Li, M. Thijssen, A. A. Abdo, F. M. Sanai, D. Dela Cruz, M. Fe F. Bohol, M. R. Al-Anazi, M. N. Al-Ahdal

**P188** **Hepatitis D virus prevalence in hospitalized patients infected with the Hepatitis B virus**  
A. Benea, L. Stanca Pandrea, Chiorean E., Bandi S., L.M. Junie\* (Cluj-Napoca, Romania)

**P189** **The automated DiaSorin LIAISON® XL Murex Anti-HDV: an innovation for HDV infection diagnosis and screening**  
C. Rocco, R. Bonavolta, L. Vallefucio, R. Sorrentino, U. Braschi, G. Portella\* (Napoli, Italy)

**P190** **Patient acceptability and Efficacy of Simeprevir in addition to peginterferon and ribavirin hepatitis C genotype 1 infection**  
Withdrawn by the author

**P191** **How do we investigate an EQA failure? Lessons learnt from a Hepatitis C RNA detection distribution**  
B. Kele\* (London, UK), P. Jovanovic, E. Elenoglo, H. Seyedzade, S. Whitmor, S. Rughooputh

**P192** **Viral hepatitis during pregnancy**  
E. Puca\*, G. Stroni, I. Akshia, E. Qyra, M. Qato, M. Deda, E. Muco, P. Pipero (Tirane, Albania)

**P193** **Trends of hepatitis C virus genotypes in chronic HCV patients in Greece during the 2004-2016 period. Genotype association with viral load**  
A. Kalliaropoulos, B. Martinez-Gonzalez\*, D. N. Sgouras, A.F. Mentis (Athens, Greece)

**P194** **HBV serological markers as affordable predictors of intrahepatic HBV reservoir and liver fibrosis in HBeAg-negative Chronic Hepatitis B Infection**  
R. Salpini\* (Rome, Italy), U.S. Gill, A. Battisti, L. Piermatteo, L. Colagrossi, N. Hansi, C.

F. Perno, F. Ceccherini-Silberstein, P.T.F. Kennedy, V. Svircher

**P195** **Hepatitis A virus genotype IIIA in Denmark; A Christmas tradition?**  
S. Midgley\*, L. Müller, K. Vorborg, H. T. Vestergaard, T. K. Fischer (Copenhagen, Denmark)

**P196** **The hcv core+1/arfp may serve as a novel marker for the progression of liver disease**  
K. Kassela, I. Karakasiliotis\* (Athens, Alexandroupoli, Greece), T. Mylopoulou, N. Intzes, M. Bikou, J. Koskinas, K. Mimidis, C. Sarrazin, G. Grammatikos, P. Mavromara

**P197** **Low prevalence of hepatitis C antibodies and active infection in a population-based survey using a point-of-care test in Valencia, Spain, 2015-2017**  
Â. Carvalho-Gomes, A. Cubells, C. Pallarés, V. Hontangas, I. Conde, T. Di Maira, S. Peiró, G. Sanfeliu-Gimeno, F.X. López-Labrador\* (Valencia, Madrid, Spain), M. Berenguer

**P198** **Potential contribution of more sensitive hepatitis B surface antigen assays to detect and monitor hepatitis B infection**  
C. Pronier\* (Rennes, France), L. Boizeau, D. Candotti, J. Bomo, S. Laperche, V. Thibault

**P199** **Cytomegalovirus induced hepatitis in immunocompetent adult patients**  
A. Mathioudaki\*, G. Vougiouklakis, E. Barbounakis, E. Xenaki, G. Sourvinos, D.P. Kofteridis (Heraklion, Greece)

## Congenital & Neonatal Viral Infections

**P200** **A single centre real-world evaluation of nine infectious disease assays on the Roche cobas e 801 versus the Abbott Architect or Diasorin Liaison XL platform**  
E. Anckaert\* (Brussels, Belgium), J. Schiettecatte, M. Depypere, M. Klinkicht, W. Melchior

**P201** **Sepsis-like disease in neonates and young infants caused by human parechovirus**  
T. Uršič\* (Ljubljana, Slovenia), M. Sagadin, U. Glinšek Biškup, T. Avramoska, P. Fister, M. Petrovec

**P202** **What positive predictive value of seroconversion or rubella igm in diagnosis of maternal rubella infection? Four-years review of french national reference laboratory for rubella**  
E. Bouthry, C. Perillaud-Dubois\*, P. Lebraud,



## Posters' Index / Poster Sessions

MP. Soutière, L. Grangeot-Keros, C. Vauloup-Fellous (Villejuif, France)

- P203** **Integration of Congenital Cytomegalovirus testing via Dried Blood Spot into neonatal hearing screening program: a valuable further approach?**

L. Pellegrinelli\*, C. Galli, V. Primache, M. Aldé, E. Pariani, U. Ambrosetti, S. Binda (Milan, Italy)

- P204** **Evaluation of new rubella igg assay on liaison XL NRL laboratory for rubella, France, 2017**

E. Bouthry, C. Perillaud-Dubois\*, MF. Lepetitcorps, A. Jadoui AM Roque-Afonso, C. Vauloup-Fellous (Villejuif, France)

- P205** **Congenital Cytomegalovirus infection and maternal varicella during pregnancy... coincidence?**

C. Périllaud-Dubois\* (Villejuif, France), E. Bouthry, F.-C. Javaugue, A. Letourneau, A. Bonnin, E. Letamendia, A. Benachi, A.-M. Roque-Afonso, C. Vauloup-Fellous

- P206** **Severe symptomatic congenital Cytomegalovirus infection due to maternal CMV primary infection after 20 weeks of gestation**

C. Périllaud-Dubois\* (Villejuif, France), A. Bonnin, E. Bouthry, A. Letourneau, E. Letamendia, A. Benachi, A.-M. Roque-Afonso, C. Vauloup-Fellous

- P207** **Clinical and economical impact of an adenovirus keratoconjunctivitis outbreak in a neonatology unit**

M. Echavarria\*, D. Marcone, F. Angueyra\*, F. Desmery, D. Albas, Y. Rubies, C. Ricarte, C. Videla, V. Romano, J. Dominguez, S. Vidaurreta, G. Carballal (Buenos Aires, Argentina)

- P208** **Unexpected detection of human herpesvirus type 6 (HHV-6) DNA in the CSF of one of two twins with perinatal herpes simplex virus type 1 (HSV-1) infection**

S.A. Nordbø\*, S. Krokstad, H. Bergseng (Trondheim, Norway)

- P209** **Primary CMV infection in pregnancy: diagnostic value of CMV-PCR in neonatal urine and saliva at birth**

S. Exler, A. Daiminger, G. Schalasta, M. Enders\* (Stuttgart, Germany)

- P210** **Pregnancy in a woman with persistently high EBV viral loads in association with Hydroa Vacciniforme**

A. Botgros\*, H. Fassihi, E. MacMahon\* (London, UK)

- P211** **Universal neonatal cytomegalovirus screening raises awareness in pediatricians and parents?**

E. Vanlaere\* (Ghent, Belgium), C. Verfaillie, A. Van den Abeele, I. Dierickx, V. Staelens, J. Van Acker

- P212** **Analysis of the prevalence of anti CMV and anti *Toxoplasma gondii* IgG antibody at prenatal screening with three fully automated assays**

F. Genco\* (Pavia, Italy), V. Meroni, E. Bouthry

- P213** **Positive predictive value of CMV IgM**

C. Perillaud-Dubois\*, E. Bouthry, A. Jadoui, A. Ling Leng, A.-M. Roque-Afonso, C. Vauloup-Fellous (Villejuif, France)

- P214** **Detection of Zika Virus, Cytomegalovirus and Human Papilloma Virus in Cervical Cytology Samples of Pregnant women from Guayaquil, Ecuador, using three molecular assays**

H. Zambrano\* (Gent, Belgium/ Guayaquil - Ecuador) A. Lee, K. Vera, M. Schetino, L. Rivera, C. Ordoñez, V. Hutse, D. Vanden Broek

- P215** **Evaluation of the effectiveness of Hepatitis B (HB) vaccination of newborns from HBsAg-positive mothers followed by the national enlarged vaccination program including HB in the health district of Tokombéré, Cameroon**

F. Lunel-Fabiani\* (Angers, France), J. Birguet, A. Pivert, R. Njouom, A. Ducancelle, A. Gautheret, T. Yaouba, P. Amta, A. Deudeu, J.M. Huraux†, J.P. Adoukara, H. Le Guillou-Guillemette, P. Veillon

- P216** **High prevalence of anti-ZIKV antibodies in asymptomatic newborns in North region of Brazil**

RRG. Machado\* (São Paulo, Brazil), DB. Araujo, DBL. Oliveira, VB. Silveira, BS. Costacurta, CP. Soares, FBL. Oliveira, LCS. Ferreira, LMA. Camargo, BFR. Ribeiro, EL. Durigon

- P217** **Congenital Cytomegalovirus infection in Denmark; risk factors and outcome.**

H. Vestergaard\* (Copenhagen, Denmark), I. Johanson, I. Panum, B. Edholm, L. Nielsen, M. Kragh Thomsen, H. Owen, L. Jensen, M. Bille





# Posters' Index / Poster Sessions

## Diagnostic Advances in Clinical Virology I / Point-of-Care Diagnostics

- P218** **Evaluation of two molecular systems and assays for the quantitative detection of HIV-1 RNA**  
H.T. Tjhie\* (Veldhoven, The Netherlands), I.S. Kwa, L.I.P.M. Donders, P.T.W. van Alphen, R.T.J.M. Roymans, J.H.B. van de Bovenkamp
- P219** **Varicella-Zoster Virclia® Igg Monotest Vs. Vidas®**  
R. van Gessel\*, R.T.J.M. Roymans, H.T. Tjhie (Veldhoven, The Netherlands)
- P220** **Evaluation of the MultiCode®-RTx PCR assays for diagnosis of CMV, EBV, HSV and VZV infection disease in clinical samples**  
K.H. Chan\*, Kitty H.K. KU (Hong Kong, China)
- P221** **Evaluation of Panther Fusion respiratory panel assays (Hologic) on respiratory samples**  
K. Beuselinck\*, K. Bruyninckx, K. Lagrou (Leuven, Belgium)
- P222** **Clinical performance of a new highly multiplexed respiratory virus assay developed by Speedx**  
S. Bone\*, S. Nair, S. Erskine, N. Lima, P. Thailavappil, R. Seehoo, L. Tan, I. Carter, J. Kok, S. Chen and E. Mokany (Sydney, Australia)
- P223** **Direct comparison of the Cobas® Liat® System for Influenza A/ B and Respiratory Syncytial Virus with the FastTrack Respiratory syndromic panel on the Roche FLOW system utilising Sigma Virocult® transport media and nasal pharyngeal aspirates**  
J. Laughlin\* (London, UK)
- P224** **VZV-loop mediated isothermal amplification assay for rapid diagnosis of breakthrough varicella**  
Y. Higashimoto\* (Toyoake, Aichi, Japan), Y. Kawamura, A. Kuboshiki, F. Hattori, H. Miura, N. Nishimura, T. Ozaki, M. Ihira, T. Yoshikawa, and Nagoya VZV study group.
- P225** **Standardization of CMV, EBV, B19V, BKV and HHV6 quantification results using conversion factors considering the matrix effect**  
P. Marechal\* (Verniolle, France), F. Gelas, M. Bonabaud, M. Dube, M. Arlaud C., A. Derome, A. Turc, C. Vidal, M. Muntaner, C. Barranger, M. Joannes
- P226** **Performance of a line immunoassay based upon recombinant Epstein-Barr virus antigens for diagnosis of primary EBV infection**  
K.H. Chan\*, C. Y. Pang, H.L. Tong (Hong Kong, China)
- P227** **Multi-center evaluation of a new molecular diagnostic assay to facilitate the analysis of Norovirus infections**  
T. Grewing\* (Hamburg, Germany), S. Charpian, U. Eigner, N. Hefner, J. Dreier, T. Vollmer, H. Petersen, S. Simon
- P228** **Implementation of a rapid multiplex PCR assay for the diagnosis of viral meningitis/encephalitis at an academic medical center in New York City**  
S. Whittier\* (New York, NY, USA)
- P229** **Detection of influenza and respiratory syncytial virus by novel rapid detection system LIAISON® MDX and its evaluation**  
A. Briksi\*, B. Spatna, V. Novakova, J. Sumova, P. Chramostova, P. Hubacek, M. Zajac (Prague, Czech Republic)
- P230** **Detection of viral nucleic acids in endomyocardial biopsies in acute and chronic heart inflammation - 5-year Polish experience**  
Withdrawn by the author
- P231** **Comparative study of antigen and molecular test for the detection of influenza virus from direct sample**  
L. Armendáriz, G. Reina, M. Iñigo, P. Sanz, I. Echarte, MC Gil, M. Fernández Alonso\* (Pamplona, Spain)
- P232** **Efficacy of a novel neutralisation collection device for molecular detection of a number of respiratory targets**  
J. Laughlin\* (London, UK)
- P233** **Comparison between the Realstar® CMV PCR kit (Altona Diagnostics®) and CMV R-gene™ (bioMérieux®) for CMV quantification follow-up in plasma and whole blood samples using IU and a single extraction**  
M. Gomes-Mayeras, S. Hantz, S. Alain\* (Limoges, France)
- P234** **Transforming Routine Laboratory Developed Tests Using Hydrolysis Probe Chemistry into Cassette Based Molecular Assays for use on the Luminex ARIES® System**  
S. Jones, A. Short and C. Moore\* (Cardiff, UK)
- P235** **Are point-of-care ME tests sensitive enough for diagnostic use in CSF samples?**  
M.K. van Genne\*, D. Riedstra and H.G.M. Niesters (Groningen, The Netherlands)
- P236** **First comparative evaluation of molecular methods for a standardized**

## Posters' Index / Poster Sessions

**quantitative measure of TTV viremia, the new surrogate marker of immune system function**

Withdrawn by the author

**P237 External Quality Assessment (EQA) pilot study for diagnosis of sepsis using molecular diagnostics**

E. McCulloch\* (Glasgow, UK), J. Rossen, K. Wiltink and P. Wallace

**P238 Implementation of a point-of-care influenza test in a tertiary acute centre in London**

J. Hart\*, T. Cutino-Moguel, N. Easom, S. Ahmed, P. Grant, B. Holgado, P. Cohen, A. Jeannes, M. Brown, S. Elkhodhair, H. Harvala, E. Sanchez, E. Nastouli (London, UK)

**P239 Assessment of blood enterovirus PCR testing in paediatric populations with fever without source, sepsis-like disease, or suspected meningitis: a prospective, multicentre, observational study**

J. Lafolie\* (Clermont-Ferrand, France), A. Labbé, A.S. L'Honneur, F. Madhi, B. Pereira, M. Decobert, M.N. Adam, F. Gouraud, F. Faibis, F. Arditty, S. Marque-Juillet, M.A. Guitteny, G. Lagathu, M. Verdan, F. Rozenberg, A. Mirand, H. Peigue-Lafeuille, C. Henquell, J.L. Bailly, C. Archimbaud, on behalf of the study team of "Blood Enterovirus Diagnosis Infection (BLEDI) in paediatric population"

**P240 Evaluation of commercially available ELISA tests for Chikungunya virus IgM and IgG**

S. D'Arcangelo\*, D. Bailey, A. Bown, E. Aarons, T. Brooks (Salisbury, UK)

**P241 Feasibility study to demonstrate rapid cartridge-based identification of HPV in oropharyngeal cancer samples**

D. Guerendiain\* (Edinburgh, UK), S. Malini, A. Donovan, W. Wong, S. Campbell, B. Conn, K. Cuschieri

**P242 Quality Control of Point of Care Testing: Are current QC reagents suitable for use?**

D. Padley\*, F. Phimister, J. Duran (Potters Bar, UK)

**P243 Uncertaintycalc: an R-Based tool to define and calculate uncertainty of quantitative viral molecular tests**

A. Kossyvakis\* (Athens, Greece), A. Arnaoutis, A. Kalliaropoulos, I. Karagiannis, N. Berginc, C. Kroupis, T. Lytras, A. F. Mentis

**P244 Evaluation of self-sampling for HPV-testing in women with cervical dysplasia**

C. Cocuzza\*, M. Martinelli, A. Rizzo, G. Brenna, C. Crotti, F. Sina, S. Chiari, M. Adorni, R. Musumeci, F. Landoni (Monza, Italy)

### Viral Gastroenteritis / CNS infections

**P245 Evaluation of BD MAX™ Enteric Viral Panel**

T.V. Madsen\*, X.C. Nielsen (Slagelse, Denmark)

**P246 Molecular epidemiology and phylogeography of enterovirus A71 in Thailand, 2008-2017**

J. Phuenpa\*, C. Auphimai, S. Korkong, S. Vongpunsawad, Y. Poovorawan (Bangkok, Thailand)

**P247 Molecular characterization of human enterovirus with aseptic meningitis and encephalitis in childhood**

J. Chansaenroj\* (Bangkok, Thailand), C. Auphimai, S. Korkong, A. Laohapatcharin, Y. Poovorawan

**P248 Identification and genotyping of human rotavirus VP4 and VP7 genes in children with gastroenteritis in Qom, Iran**

S. Shams\* (Qom, Iran), D. Mousavi Nasab, H. Heydari

**P249 Spectrum of viruses and other pathogens in gastroenteritis patients from Singapore**

E.X. Chen\*, W. L. Tan, K. L. Lim, K. S. Chan, and L. L. E. Oon (Singapore, Singapore)

**P250 Rotavirus A genotypes in the Czech Republic: Increasing proportion of G8P[8] strains**

R. Moutelíková\* (Brno, Czech Republic), J. Prodělalová, M. Dvořáková-Heroldová, V. Holá, P. Sauer

**P251 Detection of rotavirus A with enzymatic immunoassay and rapid chromatographic test compared with quantitative RT-PCR**

J. Prodělalová\* (Brno, Czech Republic), R. Moutelíková, M. Dvořáková-Heroldová, V. Holá, P. Sauer

**P252 Validation of immunochromatographic method for rapid detection of norovirus, rotavirus and adenovirus in**







# Posters' Index / Poster Sessions

## stool samples compared with genomic amplification assays.

L. González-Serrano\*, M. Muñoz, R. Gonzalez, MF Portero-Azorín, MJ. Amaro, P. Higuera, M. Cabrerizo (Madrid, Spain)

### **P253** Detection of rotavirus antigen in human stool specimens by an immunochromatographic method

A. K. Karakus, K. Yuce, H. Kahraman Durak, B. Dinc, K. Caglar, G. Bozdayi\* (Ankara, Turkey)

### **P254** Genotyping of rotavirus immunochromatography positive patients by RT-PCR

K. Albakkour, A. Altay-Kocak\*, G. Bozdayi, A. Kalkanci, K. Caglar, N. Sultan (Ankara, Turkey)

### **P255** Rotavirus infection among vaccinated children

R. Pérez-Ortín, S. Vila-Vicent, N. Carmona-Vicente, C. Santiso-Bellón, J. Rodríguez-Díaz, J. Buesa\* (Valencia, Spain)

### **P256** Symptomatic rotavirus infections occur preferentially in Secretor (FUT2 +) and Lewis-positive children

R. Pérez-Ortín, S. Vila-Vicent, N. Carmona-Vicente, C. Santiso-Bellón, J. Rodríguez-Díaz, and J. Buesa\* (Valencia, Spain)

### **P257** HBoV detected in CSF: Is it the etiological agent?

C. Cicek, A. Zeytinoglu, Z. Dinc, A. Guler, M. Tasbakan, S. Erensoy\*, I. Altuglu, R. Sertoz (Izmir, Turkey)

### **P258** Evaluation of the ARIES® Norovirus assay in a retrospective study of 100 stool samples

C. Lynen\*, H. Peltroche, T. Juretzek (Cottbus, Germany)

### **P259** Occurrence, activity and impact of human parvovirus persistence in diseased and healthy intestinal tissues

M. Xu\* (Helsinki, Finland), K. Leskinen, V. Groma, Y. Wang, A. Lepistö, K. Hedman, T. Sipponen, P. Saavalainen, and M. Söderlund-Venermo

### **P260** Post-herpetic encephalitis (HE) cerebral abscess: viral reactivation or latency site within central nervous system (CNS)?

M. Catroux, A. Larivière, M. Garcia, N. Lévêque, G. Le Moal, D. Boutolleau, F. Roblot, S. Burrel\* (Poitiers, France)

### **P261** Diagnostic performance of a new multiplex PCR in patients with viral infections

G. Kapnisi, C. Kittas, A. Giannaki, E. Priavali, H. Sakkas, S. Levidiotou, K. Gartzonika\* (Ioannina, Greece)

### **P262** Contribution of Enterovirus and Parechovirus in patients hospitalized with neurological impairment in

## Northern Italy (2015-2017)

L. Pellegrinelli\* (Milan, Italy), A. Piralla, C. Galli, F. Giardina, S. Binda, E. Pariani, F. Baldanti

### **P263** Genetic diversity of enterovirus in cerebrospinal fluid in Belgium in 2017

E. Wollants, E. Keyaerts\*, A. Rector, M. Van Ranst (Leuven, Belgium)

### **P264** Gastroenteritis outbreak by two rare Norovirus strains; GI.P2\_GI.2 and the recombinant GII.P16\_GII.13 strain in a touristic area, Chalkidiki, Northern Greece, August 2015.

K. Tryfinopoulou\* (Athens, Greece), M. Kyritsi, K. Mellou, F. Kolokythopoulou, A. Katsiafliaka, M. Potamiti-Komi, A. Lamprou, Th. Georgakopoulou, C. Hadjichristodoulou

### **P265** Real-time gastrointestinal disease surveillance through cloud based epidemiology network in the EU, United States, and Latin America

C. Wilson\*, J. Jones, H. Niesters, Trend Working Group, C. Cook, L. Meyers (Groningen, The Netherlands)

### **P266** Detection of central nervous system (CNS) pathogens by multiplex PCR in cerebrospinal fluid (CSF) samples

R. Can Sarinoğlu\*, B. Aksu, B. Saran, G. Söyletir (Istanbul, Turkey)

### **P267** Evaluation of the Luminex ARIES® Norovirus assay on fecal samples and swabs.

L. Peeters\* (Lier, Belgium), D. Obbels, J. Frans, A. Goovaerts, M. Raymaekers, R. Cartuyvels, E. Van Even and W. Laffut

### **P268** Molecular epidemiology of enteroviral CNS infections in northern Greece

E. Papadopoulou, S. Pappa\*, K. Tsergouli, A. Papa (Thessaloniki, Greece)

### **P269** Inhibition of Herpes simplex virus type 1 infection in human oligodendrocytic cells by valproate derivatives

B. Praena\*, R. Bello-Morales, C. de la Nuez and J. A. López-Guerrero (Madrid, Spain)

### **P270** Pharmacokinetics (PK) and safety of a first in class antiviral (CMX521) for human norovirus in healthy adult subjects

M. Morrison\*, M. Anderson, T. Arumugham, V. Schuck, J. Dunn, and O. Naderer (Durham, NC, USA)

### **P271** Emergence of rotavirus G12 in a neonatal intensive care unit in Ankara Transferred to oral presentations

### **P272** Epidemiology of enteric viruses in children with gastroenteritis in Ogun State, Nigeria

Withdrawn by the author

## Posters' Index / Poster Sessions



**P273 Emerging rotavirus genotypes G10 and G12 in patients with acute gastroenteritis in Turkey**  
H. Kahraman, A. Altay-Kocak\* (Ankara, Turkey), K. Albakkour, H. Muftah, B. Dalgic, K. Caglar, K. Ahmed, G. Bozdayi

**P274 High-resolution Cryo-EM of Fab-labeled HPeV3 provides mechanistic insights into neutralization and assembly**  
A. Domanska\*, J. W. Flatt, J. J. J. Jukonen, J. A. Geraets, S. J. Butcher (Helsinki, Finland)

**P275 Emergence of norovirus GII.2 and novel GII.4 variants in South Greece**  
M. Lafazani\*, N. Siafakas, G. Chronopoulou, S. Pournaras (Athens, Greece)

### HIV / Sexually transmitted viral infections

**P276 HIV-1 protease containing a leucine zipper fused at the N-terminus exhibits activity in a linker amino acid dependant manner**  
FH. Yu, CT. Wang\* (Taipei, Taiwan)

**P277 HIV/AIDS knowledge of pharmacy students and their attitudes towards people living HIV**  
Withdrawn by the author

**P278 Staging of HIV infections utilising commonly used HIV serological assays**  
J. Hassan\*, J. Moran, J. Connell, C. De Gascun (Dublin, Ireland)

**P279 False positive HTLV serology after intravenous immunoglobulin treatment**  
K. Malm\* (Örebro, Sweden), C. Almgren-Lidman, O. Stromberg, M. Sundqvist, S. Andersson

**P280 Performance Evaluation of the Aptima® HIV-1 Quant Dx and Aptima® HBV Quant assays on the fully automated Panther in comparison to COBAS® 6800/8800 HIV-1 and HBV tests**  
A. Ebel\*, C. Bali, L. Guis, S. Merlin (Ivry-Sur-Seine, France)

**P281 A laboratory follow-up audit of newly detectable HIV-1 RNA between 20-199 copies/ml**  
B. Hanumunthadu\*, M. Sudhanva (London, UK)

**P282 Development of Engineered Nanocarrier for Controlled Delivery of a Protease Inhibitor**  
Withdrawn by the author

**P283 The laboratory diagnosis of HIV infections with PCR and ELISA**  
Withdrawn by the author

**P284 Development of a Reference Material for the Molecular Detection of HPV Primary Screening**  
K. Doris, C. Santirso Margaretto\*, R. Anderson and N. Almond (Potters Bar, UK)

**P285 Age and Gender Distribution of the Follow-up AIDS Patients by Real-Time PCR**  
H. Muftah\*, A. Altay-Kocak, C. Dogu-Tok, K. Hizel, Isil Fidan, G. Bozdayi (Ankara, Turkey)

**P286 Timely Plasma Separation Is Crucial to Avoid False Positive Viremia with Cobas HIV-1 Viral Load Assay.**  
Wiesmann F\*, Haase B., Braun P., Knechten H. (Aachen, Germany)

**P287 Serological Results of Other Important Infectious Diseases In Hiv (+) Patients**  
Withdrawn by the author

**P288 Detection of HIV-1 transmitted drug resistance mutations using next generation sequencing compared to Sanger sequencing method**  
R. Can Sarınoğlu\*, B. Aksu, U. Hasdemir, U. Sili, A. Tekin, V. Korten, G. Söyletir (Istanbul, Turkey)

**P289 One year experience in HIV Ag/ab blood donor screening with HIV Combo test (VITROS® Immuno-diagnostic products)**  
B. G. Holmgren\*, H. Larsson, C. Bohn Christiansen (Lund, Sweden)

**P290 Seroprevalence and risk factors of Herpes Simplex Virus Type-2 among Tunisian adult**  
H. Naija\*, Z. Jemni, R. Allani, S. Asli, R. Dhaoui, F. Barguelli, M. Ben Moussa (Tunis, Tunisia)

**P291 Epidemiological profile and molecular characterization of HIV-1 in women at public hospital in the south of Brazil**  
T. Bessani Strapasson, S. Mara Raboni, J. Stadinicki dos Santos, A. Nayara Ferin, L. Rosele Renaud Vidal, C. Eliza Lopes Ribeiro, S. Monteiro De Almeida, R. von Linsingen, M. Bordignon Nogueira\* (Paraná, Brazil)

**P292 Quantifiable expansion of a drug-resistant HIV-1 population observed**





# Posters' Index / Poster Sessions

using a NGS-based genotyping and resistance assay.

J. Dean, C. Bannan, M. Neary, N. Lynn, A. Goertz, G. Michel, C. Lee, S. Coughlan\* (Dublin, Ireland), C. Bergin & C.F. De Gascun

**P293 High prevalence of Kaposi's sarcoma-associated virus in HIV PrEP users**

A. Jary\*, R. Palich, V. Leducq, G. Monsel, F. Caby, R. Muzzafar, S. Imbert, L. Schneider, A. Simon, V. Calvez, C. Katlama, A-G. Marcelin (Paris, France)

**P294 HIV-1 Resistance Testing - Experiences from INSTAND EQA Schemes 2014 - 2017**

M. Kammel\* (Berlin, Düsseldorf, Germany), A. Wehner, V. Lindig, O. T. Keppler, J. Eberle, L. Gürtler, V. A. J. Kempf, H. F. Rabenau, A. Berger, K. Überla, K. Korn, F. Klein, R. Kaiser, E. Heger, E. Knops, M. Stürmer, M. Obermeier, M. Schütze, H.-P. Grunert and H. Zeichhardt

**P295 HIV infection, monitoring, diagnosis, therapy and prophylaxis aspects, in Romania**

I. Filipesco, C. Jianu, C. Itu, M. Lupse, L. M. Junie\* (Cluj-Napoca, Romania)

## Diagnostic Advances in Clinical Virology II / Clinical Metagenomics

**P296 Variability and phylogeny of community human herpesvirus 6 (HHV-6A and -6B) and inherited chromosomally integrated (iciHHV-6A and -6B) strains in France**

P. Bonnafous\* (Paris, France), M. Le Gouil, D. Loureiro, E. Guilleminault, J. Gozlan, H. Agut and A. Gautheret-Dejean

**P297 Genotyping of Mumps (parotitis) virus using the HN gene**

L. D. Rasmussen\*, D. J. Schmidt & T. K. Fischer (Copenhagen, Denmark)

**P298 Acyclovir-resistant herpetic keratitis (HK) in an immunocompetent patient**

A. Robinet-Perrin, C. Tumiotto, T. Cornut, A. Santoni, I. Garrigue, D. Boutolleau, S. Burrel\* (Paris, France)

**P299 Inter-Individual and In-Host Genetic Diversity of Persistent DNA Viruses**

L. Pyöriä\*, M. Toppinen, L. Hedman, A. Sajantila, K. Hedman, M.F. Perdomo (Helsinki, Finland)

**P300 MicroRNAs as potential biomarkers for detection and staging of active Human Cytomegalovirus infection**

N. Goulidaki\* (Heraklion, Greece), C. Polytarchou, D.A. Spandidos, D. Iliopoulos, G. Sourvinos

**P301 Technical and clinical validation of a novel, highly sensitive IFN- $\gamma$  ELISpot assay to monitor CMV-specific cell-mediated immunity in immunocompromised patients**

S. Barabas, T. Spindler, R. Kiener, T. Lugner, J. Batzilla, M. Schemmerer, J. Köstler, H. Bendfeldt, A. Rasclé, C.A. Böger, B. Krüger, B.K. Krämer, R. Wagner, B. Banas, and L. Deml\* (Regensburg, Germany)

**P302 A novel DNA extraction method by gold nanoparticle based for specific isolation and detection of high risk human papillomaviruses from tissue samples**

Withdrawn by the author

**P303 Analysis of the signification of the internal control of 11 Rapid Diagnostic Tests (RDTs) for Human Immunodeficiency Virus infection screening**

V. Gauthier, I. Leroy, F. Conan, A. Gautheret-Dejean\* (Paris, France)

**P304 Clinical performance of a fully automated next - generation sequencing platform for HCV resistance testing**

C. Rodriguez, A. Soulier, V. Demontant, S. Fourati, L. Poiteau, J.M. Pawlotsky, S. Chevaliez\* (Créteil, France)

**P305 Metagenomic sequencing for pathogen detection in clinical samples**

M. Lind Karlberg\*, E. Alm, N. Lagerqvist, R. Advani, G. Östlund, O. Svartström, N. Edner, A. Risberg, and K. Tegmark-Wisell (Solna, Sweden)

**P306 Advancing molecular analyses of human parechoviruses by use of a novel pan-HPeV long-range RT-PCR for swift amplification of the near-full genome**

P. E. Obermeier, B. Haldemann, P. W. Dabrowski, A. Thürmer, A. Nitsche, T. Semmler, V. Strenger, D. Michel, S. Diedrich, and S. Böttcher\* (Berlin, Germany)

**P307 Multicentre evaluation of the variability of adenovirus (HAdV) quantification by PCR; establishing the 1st WHO International Standard for HAdV for NAT**

J.F. Fryer, J.G. Hockley, S. Govind, S.L. Kempster\*, C.L. Morris, and the Collaborative Study Group (Potters Bar, UK)

**P308 Metagenomics detection and identification of viruses in routine diagnostics: comparison of performance of bioinformatic pipelines**

E.C. Carbo\*, A.L. van Rijn-Klink, N. Pappas, I. Sidorov, S. van Boheemen, H. Mei, E.C.J.

## Posters' Index / Poster Sessions



Claas, A.C.M. Kroes & J.J.C. de Vries (Leiden, The Netherlands)

**P309** **Systematic characterization of the viral bioportfolio in human soft and hard tissues.**

M. Toppinen, L. Pyöriä, N. Dahlström, L. Hedman, A.M. Sulonen, A. Sajantila, K. Hedman, M.F. Perdomo\* (Helsinki, Finland)

**P310** **Metagenomic next-generation sequencing of nasopharyngeal swabs in chronic obstructive pulmonary disease exacerbations**

A.L. van Rijn, S. van Boheemen, E.C. Claas, T.M. Eagan, P.S. Hiemstra, A.C.M. Kroes\* (Leiden, The Netherlands), J.J.C. de Vries

**P316** **Fast Track cyler - Easier and quicker diagnostic of infections with lyophilised multiplex real-time PCR assays from Fast Track Diagnostics**

A. Hagen\*, M. Gollier, S. Saracino, M. Steimer (Esch-sur-Alzette, Luxembourg)

**P317** **Gut virome in infants and young children developing early stages of type 1 diabetes**

O. Cinek\* (Prague, Czech Republic), L. Kramna, G. Tapia, K. Mazankova, LC. Stene, KS. Ronningen

**P318** **A panoramic view of hemorrhagic fever with renal syndrome in Albania**

E. Puca\*, E. Qyra, G. Stroni, M. Qato, E. Tomini, M. Kote, S. Bino, P. Pipero, A. Harxhi (Tirane, Albania)

### Clinical Syndromes

**P311** **Viral conjunctivitis surveillance reveals high genotypic diversity among human adenoviruses in Shenzhen, China, from 2014 to 2017**

Y. He\*, L. Chen (Shenzhen, P.R. China)

**P312** **Evaluation of Fast Track Diagnostics multiplex real-time quantitative PCR kits on VERSANT® kPCR Molecular System**

P. Leidinger-Kaufmann\* (Esch-sur-Alzette, Luxembourg), N. Kin, P. Cruz, R. Mei, J. Saikia, M. Steimer

**P313** **FastFinder™ - faster, easier and standardized analysis for Fast Track Diagnostics' multiplex real-time PCR assays**

U. Greffrath\* (Esch-sur-Alzette, Luxembourg), S. Medves, L. Chambeau, J. Jacobs, A. Romanillos, K. Notelaers, M. Steimer

**P314** **Herpes simplex virus encephalitis in a patient with a diagnosis of schizophrenia**

M. Colak, H. Avcikucuk, H. Muftah, S. G. A. Bikmaz, B. Dinc, G. Bozdayi\* (Ankara, Turkey)

**P315** **The role of human parvovirus B19 in the pediatric patients with pancytopenia?**

M. Colak, A. Altay Kocak\* (Ankara, Turkey), Z. Kaya, U. Kocak, I. Yenicesu, G. Bozdayi



# Faculty Index

## B

### **Fausto Baldanti**

Professor, Department of Clinical, Surgical, Diagnostics and Pediatric Sciences, University of Pavia, Italy Molecular Virology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

### **Judith Breuer**

Professor, Division of Infection and Immunity, University College London, London, United Kingdom

### **Javier Buesa**

President ESCV, Professor, Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain

## C

### **Mike Catchpole**

Dr, Chief Scientist ECDC, Visiting Professor at Imperial College London and City University London, London, United Kingdom

### **Eric C.J. Claas**

PhD, Molecular Medical Microbiologist, Department of Medical Microbiology, Leiden University Medical Centre, Leiden, The Netherlands

### **Peter Coyle**

Professor, Department of Virology, Hamad General Hospital, Doha, Qatar

## D

### **Susanne Gjeruldsen Dudman**

Dr., MD, PhD, Senior Medical Officer, Head of Norwegian National Polio Enterovirus MMR Reference Laboratory, Department Vaccinepreventable Diseases, Norwegian Institute of Public Health, Oslo, Norway

## F

### **Mariet Feltkamp**

Dr., MD, PhD, Associate Professor of Medical Virology, Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands

### **Ron A.M. Fouchier**

Dr., PhD, Professor of Molecular Virology, Department of Viroscience and National influenza Center, Erasmus MC Rotterdam, The Netherlands

## G

### **Giorgio Gallinella**

Associate Professor in Microbiology, University of Bologna, Department of Pharmacy and Biotechnology, S. Orsola - Malpighi Hospital - Microbiology, Bologna, Italy

### **Paul D. Griffiths**

MD, DSc, FRCPath, Professor, Centre for Virology, University College London Medical School, London, United Kingdom

## H

### **Klaus Hamprecht**

Professor, Institut für Medizinische Virologie und Epidemiologie der Viruskrankheiten, University of Tuebingen, Germany

### **Heli Harvala**

Dr., PhD, MsC, MD, FRCPath, Consultant Medical Virologist, NHS Blood and Transplant, Colindale, London, United Kingdom

### **Randall T. Hayden**

MD, Director, Clinical Pathology Laboratories, Director, Clinical and Molecular Microbiology, Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN U.S.A.

### **Hans H. Hirsch**

Professor, Department of Biomedicine, University of Basel, Basel, Switzerland

## I

### **Jacques Izopet**

Professor of Virology, Biology Institute - Toulouse University Hospital & INSERM UMR1043 / CNRS UMR5282, National Reference Center of Hepatitis E virus, Toulouse, France

## K

### **Laurent Kaiser**

Professor, Dr. Med., Head of the Division of Infectious Diseases, Geneva University Hospital, Laboratory of Virology & Geneva Centre for Emerging Viral Diseases, Geneva, Switzerland

### **Paul Klapper**

Professor of Clinical Virology, Faculty of Biology, Medicine, and Health; Division of Infection, Inflammation and Respiratory Medicine, The University of Manchester, Manchester, United Kingdom

## Faculty Index



### **Florian Klein**

Professor, Institute of Virology, University Hospital of Cologne, Cologne, Germany

### **Thea Kølsen Fischer**

Professor, Virology Surveillance and Research Section, Department of Microbiological Diagnostics and Virology, Statens Serum Institut, Copenhagen, Denmark

### **Louis Kroes**

Professor of Medical Microbiology - Clinical Virology, Head of the Department of Medical Microbiology, Leiden University Medical Center (LUMC), Leiden, The Netherlands

## **M**

### **Andreas F. Mentis**

MD, PhD, Clinical Microbiologist, Head, Public Health Laboratories, Hellenic Pasteur Institute, Athens, Greece

## **N**

### **Maria São José Garcia Alexandre (MSJ Nascimento)**

Full Professor, Head, Microbiology Laboratory, Biological Sciences Department, Faculty of Pharmacy, University of Porto, Porto, Portugal

### **Hubert (Bert) G.M. Niesters**

Prof. Dr., Medical Molecular Microbiologist, Full Professor in Medical Microbiology / Molecular Clinical Virology, The University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

### **Svein Arne Nordbø**

MD, Senior Consultant, Department of Medical Microbiology, St. Olavs Hospital, Trondheim University Hospital & Associate Professor, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway

## **P**

### **Elizaveta Padalko**

Professor/Lecturer in Virology, Head of Laboratories of Infectious Serology and Molecular Microbiology, Ghent University Hospital; Faculty of Medicine and Biomedical Sciences, Ghent University, Ghent, Belgium

### **Paulo Paixão**

MD, PhD, Professor, Head of the Unit of Infection of the Nova Medical School / Faculdade de Ciências Médicas de Lisboa, Lisbon, Portugal

### **Marcus Panning**

Prof. Dr. med., Senior Physician Diagnostics, Institute of Virology, Center for Microbiology, Virology and Hygiene, Freiburg, Germany

### **Anna Papa**

Professor, Director of the Department of Microbiology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece

### **Elisabeth Puchhammer-Stöckl**

Professor Dr., MD, Head, Center for Virology, Medical University of Vienna, Vienna, Austria

## **R**

### **Anne-Marie Roque-Afonso**

Professor of Virology, Head of Virology Department, Director of National Reference Centre for HAV, Hôpitaux Universitaires Paris Sud - Université Paris Sud - INSERM U1993, Villejuif, France



# Faculty Index

## S

---

### **George Sourvinos**

Professor, Department of Clinical Virology, Medical School, University of Crete - Head, Laboratory of Clinical Virology, University Hospital of Crete, Greece

### **Nikos Spanakis**

Associate Professor, Department of Microbiology, Medical School, University of Athens, Athens, Greece

### **Richard Stanton**

Dr., Senior Lecturer, Cardiff University, Cardiff, United Kingdom

### **Stina Syrjänen**

DDS, PhD, FDSRCSEd (hon), Professor and Head, Department of Oral Pathology and Radiology, Institute of Dentistry, Faculty of Medicine, University of Turku & Chief Physician (co-affiliation), Department of Pathology, University Hospital of Turku, Turku, Finland

## T

---

### **Kate Templeton**

Consultant Clinical Scientist, Head of Molecular Diagnostics, Royal Infirmary, Edinburgh - Honorary Senior Lecturer in Medical Microbiology, University of Edinburgh, Edinburgh, United Kingdom

### **Athanasios Tsakris**

MD, PhD, FRCPath, Professor and Head of the Department of Microbiology Medical School National and Kapodistrian University of Athens, Athens, Greece

## V

---

### **Pamela Vallely**

Manchester Royal Infirmary, Virology, Manchester, United Kingdom

### **Alexandra Valsamakis**

MD, PhD, Professor of Pathology, Director of Clinical Virology and Molecular Microbiology Laboratories, Division of Medical Microbiology, Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD U.S.A.

### **Annemiek van der Eijk**

MD, PhD, Medical Microbiologist, Head of Unit Clinical Virology, Department of Viroscience, Erasmus MC, Rotterdam, The Netherlands

## Z

---

### **Harald zur Hausen**

Nobel Laureate

M.D., D.Sc. (Hon), M.D.s (Hon), Deutsches Krebsforschungszentrum (German Cancer Research Center), Heidelberg, Germany



# PANTHER FUSION™ EXPAND YOUR LAB'S POTENTIAL



**Visit booth G1 and get a live demo on how to run Respiratory, Virology, STI, HAI\*, Cervical Health and Lab-Developed Tests all together on the fully-automated Panther Fusion™ system.**

**Diagnostic Solutions | [Hologic.com](http://Hologic.com) | [euinfo@hologic.com](mailto:euinfo@hologic.com)**

ADS-02270-EUR-EN Rev. 001 ©2018 Hologic, Inc. All rights reserved. Hologic, The Science of Sure, Panther Fusion and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. This information is intended for medical professionals and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your local Hologic representative or write to [euinfo@hologic.com](mailto:euinfo@hologic.com).

\*In development

**PANTHER  
FUSION™**



# Industry Symposia

## Sunday 23<sup>rd</sup> September 2018

12.00 - 13.00 **GALENICA - OLIVOS SCIENCE**

**Novel Natural Antiviral Combinations against upper respiratory infections: New Perspectives (in Greek language)**

**Prof Elias Castanas**

Laboratory of Experimental Endocrinology, School of Medicine, University of Crete, Crete, Greece

**Prof. Christos Lionis**

Director of the Department of Social Medicine, School of Medicine, University of Crete, Crete, Greece

**Prof. Stergios Pirintsos**

Department of Biology, University of Crete, Heraklion, Crete, Greece, Botanical Garden, University of Crete, Rethymnon, Crete, Greece

**Prof. George Sourvinos**

Department of Clinical Virology, Medical School, University of Crete - Head, Laboratory of Clinical Virology, University Hospital of Crete, Greece



18.45 - 19.45 **QIAGEN**

**Cutting-edge workflows and clinical outcomes in integrated molecular diagnostics**

Importance of Ct values in clinical diagnostics: QIAstat-Dx Syndromic Testing vs routine methodology

**Prof. Vincent Thibault**

Head of Virology Lab, University Hospital of Rennes, France

Rapid and Fully Automated Implementation of LDTs on the NeuMoDx Molecular System

**Sundu Brahmasandra**

President and COO, NeuMoDx Molecular, USA



## Monday 24<sup>th</sup> September 2018

08.30 - 09.30 **SIEMENS HEALTHINEERS**

**Syndromic Multiplex Real-Time PCR: A Comprehensive Solution for Viral Diagnosis and Pathogens Surveillance**

**Chairman: Prof. George Sourvinos**

Department of Clinical Virology, Medical School, University of Crete - Head, Laboratory of Clinical Virology, University Hospital of Crete, Greece

1. Syndromic testing for respiratory tract infections: Why epidemiology matters

**Prof. Dr. med. Marcus Panning**

Institute of Virology, Medical Center, University of Freiburg, Freiburg, Germany

2. Clinical value of multiplex PCR syndromic approach for the diagnosis of acute viral central nervous system infections

**Prof. Anna Papa, MD, PhD**

Head of the Department of Microbiology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece





## Monday 24<sup>th</sup> September 2018

### 14.00 - 15.00 DIASORIN

#### Herpes Simplex Viral Infections: clinical overview and diagnostic implications

##### 1. Herpes Virus Infections: A Clinical Overview

**Prof. Matteo Bassetti**

Infectious Disease Division, Santa Maria della Misericordia University Hospital, Udine, Italy

##### 2. A New Comprehensive Solution for Molecular Detection of Herpes Simplex Virus Infections

**Michelle Tabb, PhD**

DiaSorin Molecular LLC, Cypress, CA USA

##### 3. Molecular Diagnosis of Viral Meningoencephalitis with the DiaSorin Molecular Simplexa Solution: Experience of the French National Reference Center for Herpesviruses

**David Boutolleau, PhD**

University Hospital La Pitié-Salpêtrière - Charles Foix, National Reference Centre for Herpesviruses, Virology Department and Sorbonne Universités, Paris, France



### 15.00 - 16.00 BIOMÉRIEUX

#### Turning innovation into patient care: Benefits of rapid, Syndromic testing

##### 15:00-15:05 Welcome Remarks

**Chairman: Prof. Christine Ginocchio**

Vice President, Scientific and Medical Affairs, BioFire Diagnostics, a bioMérieux company

##### 15:05-15:25 How rapid pathogen identification impacts care in patients with suspected meningitis / encephalitis

**Dr. Matthias Klein**

Clinical Neurologist, Ludwig-Maximilians-University Munich, Klinikum Großhadern

##### 15:25-15:40 A LEAN Point-Of-Impact respiratory test at the Emergency Department in a Tertiary Referral Hospital

**Prof. Dr. H.G.M. Niesters, PhD**

Director, Laboratory of Clinical Virology, University Medical Center Groningen, The Netherlands

##### 15:40-16:00 BioFire® FilmArray® Respiratory and ME Panels in Clinical Molecular Diagnostics Laboratory - 8 years of experience

**Ass. Prof. Dr. Darja Duh**

Head of Laboratory for Clinical Molecular Diagnostics, NLZOH, Maribor





# Industry Symposia

**Tuesday 25<sup>th</sup>** September 2018

**08.30 - 09.30 ABBOTT MOLECULAR**

**Improving the diagnostic virology test journey - discover how Alinity m can transform your molecular lab**

**Dr. Michael Palm**

Director of Scientific Affairs and Innovation, Abbott Molecular, Chicago, USA

**Dr. Jens Dhein**

Director Scientific Affairs EMEA, Abbott Molecular, Wiesbaden, Germany



**13.30 - 14.30 VELA DIAGNOSTICS**

1. HIV genotypic resistance testing in clinical practise using the Vela NGS platform

**Jacques Izopet, Prof.**

Chief of Virology Department, Institut Fédératif de Biologie CHU Toulouse, Toulouse, France

2. Verification of the 1<sup>st</sup> and 2<sup>nd</sup> version of the VELA HCV Genotyping NGS Assay

**Samir Dervisevic, Dr.**

Consultant Virologist, Norfolk and Norwich University Hospital, Great Britain

3. Preliminary Results of the new Sentosa HBV Genotyping and Resistance Assay

**Robert Ehret, Dr.**

Head Molecularbiologist, Medizinisches Infektiologiezentrum Berlin, Berlin, Germany

4. Clinical performance of a fully automated next-generation sequencing platform for HCV resistance testing

**Stéphane Chevaliez, Prof., PhD**

Head, Virology Unit CHU Mondor, Deputy Director, French National Reference Center for Viral Hepatitis B, C and delta, Créteil, France



**14.30 - 15.30 ROCHE**

**Quantification of CMV and EBV DNA in transplant patients: Challenges and opportunities**

**Alexandra Valsamakis**

MD, PhD, Professor of Pathology, Johns Hopkins University School of Medicine, Director, Molecular Microbiology and Clinical Virology Laboratories, The Johns Hopkins Hospital, Baltimore, MD, USA

**David Navarro**

MD, PhD, Professor of Microbiology, School of Medicine, Head of Division of Virology and Molecular Microbiology, Clinic University Hospital, Valencia, Spain







## Wednesday 26<sup>th</sup> September 2018

08.30 - 09.30 **CEPHEID**

### **Virology Testing for Improved Patient Impact**

1. Point of care testing for Flu/RSV in emergency department to manage winter outbreaks

**Dr Eleni Nastouli**

Consultant Virologist, University College Hospital London UK

2. New models of care for Hepatitis in hard to reach people

**Dr Stéphane Chevaliez**

Department of Virology & INSERM U841, Henri Mondor Hospital, University of Paris XII, Créteil, France

3. Simplifying HBV viral load testing and disease management

**Dr Sara Uceda**

Ospedale Maggiore Policlinico, University of Milan, Milan, Italy





# The 2018 ESCV Awardees

## Sunday 23<sup>rd</sup> September 2018

14.30 - 15.30 **Heine-Medin Award**



**Dr. Sander Herfst**  
Erasmus MC Rotterdam, The Netherlands

## Monday 24<sup>th</sup> September 2018

11.00 - 11.30 **Gardner Lectureship**



**Prof. Anna Papa**  
Aristotle University of Thessaloniki, Thessaloniki, Greece

## Tuesday 25<sup>th</sup> September 2018

09.30 - 10.00 **bioMérieux Award**



**Dr. Eric Claas**  
Leiden University Medical Center, The Netherlands

## Wednesday 26<sup>th</sup> September 2018


11.30 - 12.00 **Abbott Diagnostics Award**



**Dr. Elena Pariani**  
Università degli Studi di Milano, Italy

# Flexible Solutions

Clinical. Operational. Economic.



Luminex provides flexible solutions to support the clinical, operational, and economic needs of your healthcare system.

Come by Luminex **booth #S1** to learn more.

**Luminex**

complexity simplified.

[www.luminexcorp.com](http://www.luminexcorp.com)

\*These products are CE Marked for IVD Use.

\*\*Homebrew capabilities are only available for clinical diagnosis within the EU market segment. Performance characteristics of homebrew capabilities are determined by each individual laboratory.

©2018 Luminex Corporation. All rights reserved. Luminex, ARIES, NxTAG, VERIGENE, MultiCode, and xTAG are trademarks of Luminex Corporation, registered in the U.S. and other countries.



# General Meeting Information

## Registrations

### Pre-registration counter

For participants who have already registered. Please have the confirmation e-mail sent by the Meeting Secretariat close at hand. If you still have an outstanding payment, you may settle your account in cash or by credit card (Visa & Mastercard will be accepted). We accept only EURO (€).

### Onsite registration counter

For participants registering and paying their registration fees onsite: you will need to fill in an onsite registration form. Payment will be accepted in cash or by credit card (Visa & Mastercard will be accepted). We accept only EURO (€).

### Onsite registration fees

ESCV Members	580,00 €
Non ESCV Members	650,00 €
Research Assistants / Trainees	510,00 €
Students	510,00 €
Retired Members	230,00 €
Accompanying Members	100,00 €
Exhibitors	100,00 €

### Important Notes

- **Members** need to provide written proof of their membership when registering, otherwise non-member registration fees will apply. All ESCV Members should have financially settled their 2018 membership fee in order to benefit from the discounted registration fee
- **Research Assistants / Trainees** need to provide written proof of their position when registering, otherwise non-member registration fees will apply
- **Students** must be PhD candidates at the time of registration and need to provide written proof of their student status when registering, otherwise non-member registration fees will apply
- **Accompanying members** may not register for the event or participate in the scientific programme and may not be paid for by MedTech Europe Members.

### Registration Fees for Delegates include:

- ⊠ Admission to all scientific sessions
- ⊠ Admission to the exhibition hall
- ⊠ The meeting material (meeting bag, final programme, badge)
- ⊠ Certificate of attendance
- ⊠ Welcome Reception on the first evening
- ⊠ Coffee-breaks during the meeting
- ⊠ Lunches during the meeting

### Registration Fees for Exhibitors include:

- ⊠ Admission to all scientific sessions
- ⊠ Admission to the exhibition hall
- ⊠ Welcome Reception on the first evening
- ⊠ Coffee-breaks during the meeting
- ⊠ Lunches during the meeting

### Registration Fees for Accompanying Members include:

- ⊠ Welcome Reception on the first evening
- ⊠ One (1) half day tour



# General Meeting Information



## Name Badges

Participants will receive their badges onsite at the registration desk. The meeting badge should be worn by all participants at all times during the meeting to ensure access to the relevant areas. This includes the scientific sessions, the coffee-breaks and lunches, the exhibition area and other areas of the meeting venue as well as the social activities. Only participants wearing their meeting badge will be admitted to the above mentioned areas and activities.

The following badge colors are in use at the Meeting:


Speaker	Delegate	Chair
Industry	Visitor	

## Secretariat & Exhibition Working Hours


Days	Secretariat working hours	Exhibition working hours
Sunday 23 <sup>rd</sup> September 2018	11.00 - 20.45	12.00 - 19.45
Monday 24 <sup>th</sup> September 2018	08.00 - 21.00	09.00 - 19.30
Tuesday 25 <sup>th</sup> September 2018	08.00 - 18.30	09.00 - 18.15
Wednesday 26 <sup>th</sup> September 2018	08.00 - 14.00	09.00 - 13.00

# EurobioPlex HDV<sub>qRT-PCR</sub>

Hepatitis Delta is responsible for serious chronic hepatitis



Think **HDV** in all chronic **HBV** positive patients with any liver dysfunction



20 million people are infected with chronic viral Hepatitis D worldwide

1. Avicenne Hospital, Bobigny, France
2. Cf. Performances study indicated in the data sheet
3. F. Le Gal and all. Performance characteristics of a new consensus commercial Kit for Hepatitis D Virus RNA Viral Load quantification kit. JCM. 2016; DOI:10.1128/JCM.02027-16

## Certificates Of Attendance

All registered delegates will receive a Certificate of Attendance.

## Accreditation

The **21<sup>st</sup> Annual Meeting of the European Society for Clinical Virology, ATHENS, Greece, 23/09/2018-26/09/2018** has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **16** European CME credits (ECMEC®s).

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at [www.ama-assn.org/education/earn-credit-participation-international-activities](http://www.ama-assn.org/education/earn-credit-participation-international-activities).

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

## EACCME® Credits

Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the **evaluation form**. Cf. criteria 9 and 23 of UEMS 2016.20.

### Scientific Programme

Sunday 23 <sup>rd</sup> September 2018	4 ECMEC®s
Monday 24 <sup>th</sup> September 2018	5 ECMEC®s
Tuesday 25 <sup>th</sup> September 2018	4 ECMEC®s
Wednesday 26 <sup>th</sup> September 2018	3 ECMEC®s

The EACCME® awards ECMEC®s on the basis of 1 ECMEC® for one hour of CME with a maximum of 8 ECMEC®s per day. Cf. Chapter X of UEMS 2016.20.

## Certificate of Accreditation

To obtain a Certificate of Accreditation, delegates must complete the evaluation form **only for the sessions that they attend** during the Meeting.

At the end of the Meeting, delegates are requested to return the completed evaluation form to the registration desk. Certificates of Accreditation will be sent by e-mail, within 60 days from the completion of the Meeting.



## AltoStar® Molecular Diagnostic Workflow

Meet  
our experts  
on booth  
No. G4




### Automate your Real-Time PCR infectious disease testing

- Profit from the newly developed and CE-IVD marked AltoStar® workflow
- Process any sample type with one single purification kit
- Combine up to eight assays per PCR run, up to four assays per sample
- Gain full process fidelity, bidirectional LIMS interface
- Benefit from our outstanding training and support
- Choose from our broad AltoStar® assay portfolio

Join us  
for our  
Lunch Snack:  
Monday  
12:30

WORKFLOW

LIMS WORKLIST	
ID	assay A <input checked="" type="checkbox"/>
	assay B <input checked="" type="checkbox"/>
	assay C <input checked="" type="checkbox"/>



AM16 Sample Preparation

PCR Setup



CFX96™ DW

Cycler PCR



Analysis





# Presentation Guidelines



## General

The official language of the 21<sup>st</sup> ESCV Annual Meeting is **English**, therefore all types of presentations must be prepared and delivered in English. The time reserved for each presentation varies according to the presentation and session type.

## Oral Presentations

Oral presentations are organized in sessions comprising of 3 - 6 presentations according to the topic of each session. Authors are kindly asked to follow the assigned time strictly, the remaining time for the presentation and discussion will be announced and managed by the session chair.

## Supported Presentation formats

Please, prepare your presentation preferably using PowerPoint version 2010 or 2013, however versions 2007 and 2003 are also supported.

Supported file types

Presentation: PPT, PPA, PPTA, PPTX, PDF

Video: AVI, MPG, MKV, MOV, MP4, WMV

Audio: WMA, MP3, WAV

**Please note that the presentations need to be prepared in 4:3 ratio.**

## Presentation preview desk

You will be assisted in the Presentation preview desk by the technicians, who will help you upload your presentation to the intranet. You will also be able to review your presentation and to verify that it has been transferred correctly to the network.

Your presentation must be uploaded as much in advance as possible, but no later than **TWO HOURS BEFORE** the beginning of the respective session. Presentations for an early morning session must be uploaded the day before. When uploading multimedia files, do not forget to double check all your video files and all links to these multimedia that files are functional.

## In the Auditorium

Your presentation will be transferred directly to the Auditorium through the intranet.

Once the presentation is launched on the computer in the respective lecture room, you will advance your own slideshow using the remote control.

All speakers are requested to be present in the lecture room **10 MINUTES BEFORE** the session starts to meet with the session chair. Please, do not come at the last minute with your own computer into the lecture room: you will **NOT BE ABLE** to connect it. All presentations must be uploaded in the Presentation Preview desk beforehand.

In case any problems arise, there will be assistance staff in the Auditorium.



# Poster Presentations

## Dimensions of posters

- 📏 Portrait orientation
- 📏 A0 Poster size - 84,1 cm (width) x 118,9 cm (height)


Posters on several sheets are not advised.

Session	Posters to be presented	Mounting time	Presentation time	Removal date & time
Respiratory Viruses	P001 - P055	Sunday 23 <sup>rd</sup> September from 11.00 to 20.30	Monday 24 <sup>th</sup> September 19.30 - 21.00	Monday 24 <sup>th</sup> September 21.00 to 22.00 and Tuesday 25 <sup>th</sup> September 08.00 to 09.00
Viruses in the immunosuppressed host	P056 - P103			
Prevention / Vaccines	P104 - P120			
Viral Pathogenesis and Immune Responses	P121 - P133			
Emerging Viruses	P134 - P152			
Viral Oncogenesis	P153 - P158			
Hepatitis Viruses	P159 - P199	Tuesday 25 <sup>th</sup> September from 09.30 to 12.00	Tuesday 25 <sup>th</sup> September 12.30 - 13.30	Up to Wednesday 26 <sup>th</sup> September, 13.00
Congenital & Neonatal Viral Infections	P200 - P217			
Diagnostic Advances in Clinical Virology I / Point-of-Care Diagnostics	P218 - P244			
Viral Gastroenteritis / CNS infections	P245 - P275			
HIV / Sexually transmitted viral infections	P276 - P295			
Diagnostic Advances in Clinical Virology II / Clinical Metagenomics	P296 - P310			
Clinical Syndromes	P311 - P318			

### Important Notes:

- 📏 Each board will have a poster number printed and posters must be mounted to the corresponding poster board.
- 📏 Material for mounting the poster will be provided on site.
- 📏 Presenters are requested to stand by their poster during the presentation time allocated to them.
- 📏 Set-up, removal and storage of posters are the presenters' responsibility.
- 📏 Any posters remaining after the removal date & time will be disposed of by the conference staff and will not be stored.

# Innovative Solutions For Infectious Disease Testing



Rapid unitary tests • Microplate assays • Confirmatory assays  
Multiplex testing • Quality Control solutions

Visit booth #S6 to discover how our solutions can empower you to make informed decisions.

Learn more at [www.bio-rad.com/diagnostics](http://www.bio-rad.com/diagnostics)

**BIO-RAD**





# General Information

## Venue

The **Zappeion Conference & Exhibition Center** has witnessed the history of Athens for the past 120 years. It has been a key site for some of the nation's most significant moments, and has always been integrally linked to the Olympic Movement. Even though its uses were varied, it has become a landmark in the Greek capital, thus fulfilling the donor's initial wishes.

Apart from the conference rooms (with translation systems in 9 foreign languages) there are also luxurious reception areas, providing wi-fi internet connection (speed up to 24 Mbps), capability of telephone and fax support, security and control systems (fire, electricity provision, alarm, internal and external television circuit), modern areas of hygiene and other facilities systems.

## Access to the Zappeion Conference & Exhibition Center

From Athens International Airport:

### By metro

Metro Line 3. Syntagma Square is the closest metro station to the Zappeion Conference & Exhibition Center (350 m)

### By bus

Express bus X95 connects directly the Athens International Airport "El. Venizelos" to Syntagma Square (350 m)

## Athens, the host city

Each year, more and more travelers are choosing Athens for their leisure and business travel all year round. There are several reasons; Athens offers a variety of things to see and do, and most of the times, under favourable weather conditions.

Athens' transportation network is user-friendly; there are numerous museums and archeological sites and hundreds of restaurants to satisfy every taste.

Surrounded by a lining of stunning seas and mountains, Athens is filled with gems just waiting to be discovered.

Located at the crossroads of three continents, the capital of Greece with an overall population of close to four million has often been the hub of many cultures. Characterized by a culture and people that are welcoming and hospitable, every visitor just feels at home.

Athens is also an ideal congress destination, combining state-of-the-art infrastructure, excellent congress facilities and easy access from all over the world with world-class cultural attractions, modern amenities, diverse entertainment and natural beauty.

## Official Language

The official language of the 21st ESCV Annual Meeting is English.

## Banking Facilities and ATMs

Banks in Athens are generally open from Monday to Friday, from 08:00 to 14:30. There are cash machines (ATMs) nearby. The closest one is 2 minutes walking distance from the meeting venue.

If you require additional information, please ask at the registration desk staff. They will be able to direct you to the closest bank.

## Insurance, Liability

All participants are reminded that the ESCV 2018 Annual Meeting Organization (ESCV, PCOs and Meeting Venue) are not liable for any losses, accidents or damage to persons or private property. Participants and accompanying persons are strongly advised to make their own arrangements in respect to health, personal and travel insurance in their country of origin. Participation in all excursions, tours etc, is at personal risk.









## General Information



### In case of emergency

You can use the following numbers:

 Police	100
 Emergency Number	112
 First Aid	166
 Fire Department	199

### Internet access / Wi-fi

Wireless internet is available in all areas at the conference venue during the conference time.

### Mobile Phones

All participants are asked to switch mobile phones off or to silent mode during the scientific sessions.

### Smoking

Smoking is not permitted in closed public areas, **including the conference venue and the atrium**, airports, hotels, restaurants, shops, or workplaces and is only allowed in specifically designated areas.

### Video Recording

All keynote lectures will be video recorded. These will then be available free of charge for ESCV members as an E-learning program.

### Dress code

The dress code for the conference, including the Welcome Reception and the Greek Night Dinner, is informal.

### Time Zone

Greece is +2h GMT/UTC during standard time.

### Electricity

In Greece the electrical current is 220V, AC (50 Hz). Electrical sockets comply with European regulations.

### Currency

Since 2002, the currency used in Greece is the euro (€). One euro is divided up into 100 cents.

### Weather

While the month of September in Athens is still quite warm, the summer heat starts to cool off as the fall season approaches. The average temperature this month is 24°C (75°F), while the average low drops to 19°C (66°F), and the average high is still a warm 28°C (82°F).

# The only test for rapid routine BCID



**ePlex**

## Blood Culture Identification Panels

- Broad organism inclusivity: Detect more clinically relevant blood stream infections earlier
- Broad resistance gene panel: To aid in rapid, actionable treatment decisions and antibiotic stewardship
- Easy to use on any shift: Critical tests never have to wait until morning



Discover how ePlex BCID  
can revolutionize your lab.  
Visit [www.genmarkdx.com](http://www.genmarkdx.com)




## Social Programme



### Welcome Reception

Sunday, 23<sup>rd</sup> September 2018  
20.45

Atrium (Peristylon)  
of Zappeion Conference & Exhibition Center



### Greek Night Dinner

Tuesday, 25<sup>th</sup> September 2018  
18.45

“Amaltheia, the Place”




A short (20') bus ride from the Zappeion Conference & Exhibition Center through Poseidonos Avenue - the so-called “Athenian Riviera” - will bring us to one of the most idyllic sceneries of Attica : “Amaltheia, The Place”, a unique event venue located not by, but ON the beach, provides the perfect backdrop for a memorable Greek Night Dinner: traditional Greek *mezedes* (delicacies) and drinks, paired with popular folk dances, highlight the essence of Greek *philoxenia* (hospitality) and lift our spirits as the sun sets and the night lingers on...

Ticket (not included in the registration fee)\*: **60 € per person** (subsidized cost)

\* If you have already booked your Greek Night Dinner ticket online, you will receive it, together with your badge onsite at the registration desk



The widest, most flexible and adaptive  
menu for virus diagnosis



**LIAISON® MDX**



**LIAISON® X**

See our detailed menu on [molecular.diasorin.com](http://molecular.diasorin.com) and [diasorin.com](http://diasorin.com)

 **DiaSorin**  
Molecular

**DiaSorin**  
in Diagnostic Specialties

Product availability subject to required regulatory approval





## Patients Come First

### Fast, On-demand Testing for Better Patient Management

At Cepheid, improving the patient experience is our first priority. We are committed to delivering the most innovative and comprehensive virology products for the detection of HIV, hepatitis C and hepatitis B. We are focused on providing fast and actionable results that improve patient outcomes in the most vulnerable populations.



Xpert® HIV-1 Viral Load  
Xpert® HIV-1 Qual  
Xpert® HCV Viral Load  
Xpert® HCV VL Fingerstick  
Xpert® HBV Viral Load\*


Cepheid powers same-day results to aid linkage to care worldwide.  
Learn more at [cepheidinternational.com](http://cepheidinternational.com).

CE-IVD. For in vitro diagnostic use. Not available in all countries. Not available in the United States.  
\* Projected release Q3 2016 ex US

 **Cepheid**  
A better way.




# Floor Plan & Exhibitors' List



## Floor Plan & Exhibitors' List

### Platinum Sponsors




### Gold Sponsors



### Silver Sponsors



### Bronze Sponsors



### Exhibitors







# Sponsors' Acknowledgement



## Platinum Sponsors



## Gold Sponsors



## Silver Sponsors



The Diagnostic Specialist





# Sponsors' Acknowledgement

## Bronze Sponsors



## Exhibitors



## Sponsors



[illegible]

## Notes

[illegible]

[illegible]



## Notes

[illegible]

# Empowering you every step of the way

## *Tailored solutions for future challenges*

version, reliability, HIV-1, viral load monitoring, unparalleled performance, HAART, **cutting-edge**,  
me, **transplant protection**, HCV, quality, HIV-2 RNA, sustained virologic response, validation, fi  
V DNA, commutability, timely, immunosuppression, **performance**, HCV dual probe assay, revers  
genital risk, process optimisation, innovation, CMV IgM, HBV, HIV-1, target assay, syphilis, au  
otyping, customisation, **diagnostic excellence**, technical, baseline viral load, i  
V I/II, sustainability, solutions, workflow, your needs, alanine aminotransferase, chronic hepatit  
ace antigen, treponemal test, anti-HBc, productivity, complex, spots, support  
actionable results, **integration**, solid organ transplant, serology, viral load mon  
HBeAg, HSV 1, LEAN methodology, turnaround time, HCV, quality,  
early infant diagnosis, strategic, plasma separation card, HBV, timely, immunc  
**BsAg**, trust, HIV-1 RNA, avidity, standardisation, HSCT, congenital, process optimisation, inr  
ility, HSV 2, workaway time, support, HCV genotyping, customisation, diagnostic excellence, tech  
, HIV-1/HIV-2 subtype determination, HTLV I/II, sustainability, solutions, **workflow**, your needs, a  
CV RNA, efficient solutions, HBV surface antigen, treponemal test, anti-HBc, productivity, comp  
ng flexibility, **HIV Duo**, clinically relevant, actionable results, integration, solid organ transplant  
ng-edge technology, toxoplasmosis, connectivity, HBeAg, HSV 1, LEAN methodology, turnaro

**A clear direction  
ahead in  
infectious diseases**

Our integrated diagnostic solutions for infectious diseases can help laboratories to confidently achieve greater efficiency in terms of costs, time and effort.

Our high quality diagnostic tests - from the initial screening to viral load testing - can empower clinicians when making actionable treatment decisions improving the outlook for patients around the world.

**Shaping the future of diagnostics together**

Find out more - visit us in **Booth P2** at the  
21st ESCV 2018, Athens, Greece  
[molecular.roche.com](http://molecular.roche.com)



Visit  
QIAGEN  
at Booth  
#P3

# QIAstat-Dx

The next generation of syndromic insights

Join QIAGEN® for a presentation of the latest clinical data from early evaluators of the QIAstat-Dx™.

Sunday, September 23

6:45–7:45pm

Learn more at [www.QIAstat-Dx.com](http://www.QIAstat-Dx.com)

Trademarks: QIAGEN®, Sample to Insight®, QIAstat-Dx™ (QIAGEN Group). Registered names, trademarks, etc. used in this document, even when not specifically marked as such, are not to be considered unprotected by law.  
06/2018 PROM-12551-001 © QIAGEN 2018, all rights reserved.

Sample to Insight





# ARGENE® SOLUTION FOR TRANSPLANT TESTING



## Discover our new **HHV6 R-GENE® KIT**

and learn more about  
ARGENE® SOLUTION  
for viral infections monitoring  
in transplant patients

PIONEERING DIAGNOSTICS  
[www.biomerieux.com](http://www.biomerieux.com)

## COME VISIT US AT BOOTH P1

### **Syndromic Testing:** **The Right Test, The First Time.**

*The World Over!*

Rapidly identify infections with  
symptom-driven testing **in about 1 hour**



BioFire® FilmArray®  
Respiratory Panel 2 *plus*



BioFire® FilmArray®  
Blood Culture Identification Panel



BioFire® FilmArray®  
Gastrointestinal Panel



BioFire® FilmArray®  
Meningitis/Encephalitis Panel

For In Vitro Diagnostic Use  
FDA Cleared and CE-IVD Marked

